https://bordet.makemeweb.dev/fr/leukemia-free-survival-surrogate-end-point-overall-survival-evaluation-maintenance-therapy-patients 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/leukemia-free-survival-surrogate-end-point-overall-survival-evaluation-maintenance-therapy-patients 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/integrating-biomarkers-clinical-trials 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/integrating-biomarkers-clinical-trials 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/integrating-biomarkers-clinical-trials 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/eortc-10041big03-04-mindact-trial-feasible-results-pilot-phase 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/eortc-10041big03-04-mindact-trial-feasible-results-pilot-phase 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/eortc-10041big03-04-mindact-trial-feasible-results-pilot-phase 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/unravelling-epigenomic-dimension-breast-cancers 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/unravelling-epigenomic-dimension-breast-cancers 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/unravelling-epigenomic-dimension-breast-cancers 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/prevention-febrile-neutropenia-chemotherapy-treated-cancer-patients-pegylated-versus-standard 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/prevention-febrile-neutropenia-chemotherapy-treated-cancer-patients-pegylated-versus-standard 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/prevention-febrile-neutropenia-chemotherapy-treated-cancer-patients-pegylated-versus-standard 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/vegf-predictive-biomarker-anti-angiogenic-therapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/vegf-predictive-biomarker-anti-angiogenic-therapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/vegf-predictive-biomarker-anti-angiogenic-therapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/microbiology-bronchoalveolar-lavage-fluid-children-acute-non-responding-or-recurrent-community 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/microbiology-bronchoalveolar-lavage-fluid-children-acute-non-responding-or-recurrent-community 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/microbiology-bronchoalveolar-lavage-fluid-children-acute-non-responding-or-recurrent-community 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/pivotal-role-innate-and-adaptive-immunity-anthracycline-chemotherapy-established-tumors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/pivotal-role-innate-and-adaptive-immunity-anthracycline-chemotherapy-established-tumors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/pivotal-role-innate-and-adaptive-immunity-anthracycline-chemotherapy-established-tumors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/cancer-du-sein-et-radiotherapie-peroperatoire-par-electrons-revue-des-100-premieres-patientes 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/cancer-du-sein-et-radiotherapie-peroperatoire-par-electrons-revue-des-100-premieres-patientes 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/cancer-du-sein-et-radiotherapie-peroperatoire-par-electrons-revue-des-100-premieres-patientes 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/humanitarian-ethics-and-notion-justice 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/humanitarian-ethics-and-notion-justice 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/humanitarian-ethics-and-notion-justice 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/breathe-contributes-ers-action-plan-thoracic-oncology 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/breathe-contributes-ers-action-plan-thoracic-oncology 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/breathe-contributes-ers-action-plan-thoracic-oncology 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/pappillary-serous-carcinoma-peritoneum-after-risk-reducing-salpingo-oophorectomy-rrso-women-brca1 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/pappillary-serous-carcinoma-peritoneum-after-risk-reducing-salpingo-oophorectomy-rrso-women-brca1 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/pappillary-serous-carcinoma-peritoneum-after-risk-reducing-salpingo-oophorectomy-rrso-women-brca1 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/mtor-inhibition-rcc-proof-concept-clinical-use-and-future-directions 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/mtor-inhibition-rcc-proof-concept-clinical-use-and-future-directions 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/mtor-inhibition-rcc-proof-concept-clinical-use-and-future-directions 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/strategies-subtypes-dealing-diversity-breast-cancerhighlights-st-gallen-international-expert 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/strategies-subtypes-dealing-diversity-breast-cancerhighlights-st-gallen-international-expert 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/strategies-subtypes-dealing-diversity-breast-cancerhighlights-st-gallen-international-expert 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/prevention-neutropenia-related-events-elderly-patients-haematological-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/prevention-neutropenia-related-events-elderly-patients-haematological-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/prevention-neutropenia-related-events-elderly-patients-haematological-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/late-complication-percutaneous-radial-artery-cannulation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/late-complication-percutaneous-radial-artery-cannulation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/late-complication-percutaneous-radial-artery-cannulation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/low-dose-intravenous-ketamine-and-clonidine-poor-postoperative-opioid-responsiveness-double-blind 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/low-dose-intravenous-ketamine-and-clonidine-poor-postoperative-opioid-responsiveness-double-blind 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/low-dose-intravenous-ketamine-and-clonidine-poor-postoperative-opioid-responsiveness-double-blind 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/remifentanil-patient-controlled-analgesia-effect-site-target-controlled-infusion-compared-morphine 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/remifentanil-patient-controlled-analgesia-effect-site-target-controlled-infusion-compared-morphine 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/remifentanil-patient-controlled-analgesia-effect-site-target-controlled-infusion-compared-morphine 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/diverticulum-urachus 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/diverticulum-urachus 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/diverticulum-urachus 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/occurrence-putative-virulence-genes-arcobacter-species-isolated-humans-and-animals 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/occurrence-putative-virulence-genes-arcobacter-species-isolated-humans-and-animals 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/occurrence-putative-virulence-genes-arcobacter-species-isolated-humans-and-animals 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/transmission-multiple-resistant-salmonella-concord-internationally-adopted-children-their-adoptive 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/transmission-multiple-resistant-salmonella-concord-internationally-adopted-children-their-adoptive 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/transmission-multiple-resistant-salmonella-concord-internationally-adopted-children-their-adoptive 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/quantitative-immunohistochemical-fingerprinting-adhesiongrowth-regulatory-galectins-salivary-gland 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/quantitative-immunohistochemical-fingerprinting-adhesiongrowth-regulatory-galectins-salivary-gland 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/quantitative-immunohistochemical-fingerprinting-adhesiongrowth-regulatory-galectins-salivary-gland 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/evaluation-18fdg-pet-ct-diagnosis-endometriosis-prospective-study 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/evaluation-18fdg-pet-ct-diagnosis-endometriosis-prospective-study 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/evaluation-18fdg-pet-ct-diagnosis-endometriosis-prospective-study 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/high-incidence-high-risk-hpv-benign-and-malignant-lesions-larynx 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/high-incidence-high-risk-hpv-benign-and-malignant-lesions-larynx 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/high-incidence-high-risk-hpv-benign-and-malignant-lesions-larynx 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/high-prevalence-high-risk-human-papillomavirus-palatine-tonsils-healthy-children-and-adults 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/high-prevalence-high-risk-human-papillomavirus-palatine-tonsils-healthy-children-and-adults 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/high-prevalence-high-risk-human-papillomavirus-palatine-tonsils-healthy-children-and-adults 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/sudden-death-young-adult-associated-bacillus-cereus-food-poisoning 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/sudden-death-young-adult-associated-bacillus-cereus-food-poisoning 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/sudden-death-young-adult-associated-bacillus-cereus-food-poisoning 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/nasal-neurothekeoma-adolescent-girl 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/nasal-neurothekeoma-adolescent-girl 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/nasal-neurothekeoma-adolescent-girl 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/chromatin-disruption-promoter-bovine-leukemia-virus-during-transcriptional-activation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/chromatin-disruption-promoter-bovine-leukemia-virus-during-transcriptional-activation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/chromatin-disruption-promoter-bovine-leukemia-virus-during-transcriptional-activation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/carcinoma-situ-bronchial-resection-margin-review 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/carcinoma-situ-bronchial-resection-margin-review 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/carcinoma-situ-bronchial-resection-margin-review 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/postoperative-radiotherapy-non-small-cell-lung-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/postoperative-radiotherapy-non-small-cell-lung-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/postoperative-radiotherapy-non-small-cell-lung-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/radiotherapy-lung-cancer-any-room-left-elective-mediastinal-irradiation-2011 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/radiotherapy-lung-cancer-any-room-left-elective-mediastinal-irradiation-2011 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/radiotherapy-lung-cancer-any-room-left-elective-mediastinal-irradiation-2011 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/therapeutic-advances-non-small-cell-lung-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/therapeutic-advances-non-small-cell-lung-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/therapeutic-advances-non-small-cell-lung-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/proteomic-changes-associated-breast-cancer-progression-mcf10at-model 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/proteomic-changes-associated-breast-cancer-progression-mcf10at-model 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/proteomic-changes-associated-breast-cancer-progression-mcf10at-model 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/time-series-evaluation-vivo-effect-letrozole-gene-expression-breast-cancer 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/time-series-evaluation-vivo-effect-letrozole-gene-expression-breast-cancer 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/time-series-evaluation-vivo-effect-letrozole-gene-expression-breast-cancer 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/gene-expression-changes-over-time-tamoxifen-treated-breast-cancer-xenograft-model 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/gene-expression-changes-over-time-tamoxifen-treated-breast-cancer-xenograft-model 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/gene-expression-changes-over-time-tamoxifen-treated-breast-cancer-xenograft-model 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/cd44-cd24-low-phenotype-and-resistance-trastuzumab-her2-positive-breast-cancer-cell-lines 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/cd44-cd24-low-phenotype-and-resistance-trastuzumab-her2-positive-breast-cancer-cell-lines 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/cd44-cd24-low-phenotype-and-resistance-trastuzumab-her2-positive-breast-cancer-cell-lines 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/genomic-grade-index-important-tool-assessing-breast-cancer-tumor-grade-and-prognosis 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/genomic-grade-index-important-tool-assessing-breast-cancer-tumor-grade-and-prognosis 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/genomic-grade-index-important-tool-assessing-breast-cancer-tumor-grade-and-prognosis 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/znf703-gene-amplification-8p12-specifies-luminal-b-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/znf703-gene-amplification-8p12-specifies-luminal-b-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/znf703-gene-amplification-8p12-specifies-luminal-b-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/genes-expressed-specific-areas-human-fetal-cerebral-cortex-display-distinct-patterns-evolution 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/genes-expressed-specific-areas-human-fetal-cerebral-cortex-display-distinct-patterns-evolution 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/genes-expressed-specific-areas-human-fetal-cerebral-cortex-display-distinct-patterns-evolution 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/assessment-ki67-breast-cancer-recommendations-international-ki67-breast-cancer-working-group 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/assessment-ki67-breast-cancer-recommendations-international-ki67-breast-cancer-working-group 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/assessment-ki67-breast-cancer-recommendations-international-ki67-breast-cancer-working-group 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/evaluation-infinium-methylation-450k-technology 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/evaluation-infinium-methylation-450k-technology 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/evaluation-infinium-methylation-450k-technology 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/breast-cancer-should-we-assess-her2-status-oncotype-dx 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/breast-cancer-should-we-assess-her2-status-oncotype-dx 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/breast-cancer-should-we-assess-her2-status-oncotype-dx 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/triple-negative-breast-cancer-proposals-pragmatic-definition-and-implications-patient-management 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/triple-negative-breast-cancer-proposals-pragmatic-definition-and-implications-patient-management 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/triple-negative-breast-cancer-proposals-pragmatic-definition-and-implications-patient-management 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/international-association-study-lung-canceramerican-thoracic-societyeuropean-respiratory-society 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/international-association-study-lung-canceramerican-thoracic-societyeuropean-respiratory-society 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/international-association-study-lung-canceramerican-thoracic-societyeuropean-respiratory-society 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/12th-annual-conference-thoracic-oncology 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/12th-annual-conference-thoracic-oncology 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/12th-annual-conference-thoracic-oncology 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/thoracic-malignancies-cisplatin-and-renal-function 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/thoracic-malignancies-cisplatin-and-renal-function 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/thoracic-malignancies-cisplatin-and-renal-function 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/paradigm-shifts-lung-cancer-defined-new-iaslcatsers-lung-adenocarcinoma-classification 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/paradigm-shifts-lung-cancer-defined-new-iaslcatsers-lung-adenocarcinoma-classification 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/paradigm-shifts-lung-cancer-defined-new-iaslcatsers-lung-adenocarcinoma-classification 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/12th-meeting-emergency-care-and-severe-complications-cancer-patient 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/12th-meeting-emergency-care-and-severe-complications-cancer-patient 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/12th-meeting-emergency-care-and-severe-complications-cancer-patient 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/immunohistochemical-study-40-cases-longitudinal-melanonychia 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/immunohistochemical-study-40-cases-longitudinal-melanonychia 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/immunohistochemical-study-40-cases-longitudinal-melanonychia 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/quality-work-life-doctors-working-cancer-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/quality-work-life-doctors-working-cancer-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/quality-work-life-doctors-working-cancer-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/tips-and-tricks-triple-negative-breast-cancer-how-manage-patients-real-life-practice 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/tips-and-tricks-triple-negative-breast-cancer-how-manage-patients-real-life-practice 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/tips-and-tricks-triple-negative-breast-cancer-how-manage-patients-real-life-practice 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/tp53-status-prediction-sensitivity-taxane-versus-non-taxane-neoadjuvant-chemotherapy-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/tp53-status-prediction-sensitivity-taxane-versus-non-taxane-neoadjuvant-chemotherapy-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/tp53-status-prediction-sensitivity-taxane-versus-non-taxane-neoadjuvant-chemotherapy-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/biological-features-and-prognosis-breast-cancer-diagnosed-during-pregnancy-case-control-study 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/biological-features-and-prognosis-breast-cancer-diagnosed-during-pregnancy-case-control-study 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/biological-features-and-prognosis-breast-cancer-diagnosed-during-pregnancy-case-control-study 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/comparisons-between-different-polychemotherapy-regimens-early-breast-cancer-meta-analyses-long-term 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/comparisons-between-different-polychemotherapy-regimens-early-breast-cancer-meta-analyses-long-term 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/comparisons-between-different-polychemotherapy-regimens-early-breast-cancer-meta-analyses-long-term 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/treatment-febrile-neutropenia-expensive-prevention-answer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/treatment-febrile-neutropenia-expensive-prevention-answer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/treatment-febrile-neutropenia-expensive-prevention-answer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/palliative-noninvasive-ventilation-patients-acute-respiratory-failure 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/palliative-noninvasive-ventilation-patients-acute-respiratory-failure 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/palliative-noninvasive-ventilation-patients-acute-respiratory-failure 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/perceptions-appropriateness-care-among-european-and-israeli-intensive-care-unit-nurses-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/perceptions-appropriateness-care-among-european-and-israeli-intensive-care-unit-nurses-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/perceptions-appropriateness-care-among-european-and-israeli-intensive-care-unit-nurses-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/differentiation-associated-regulation-microrna-expression-vivo-human-cd8-t-cell-subsets 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/differentiation-associated-regulation-microrna-expression-vivo-human-cd8-t-cell-subsets 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/differentiation-associated-regulation-microrna-expression-vivo-human-cd8-t-cell-subsets 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/reproducibility-3d-1h-mr-spectroscopic-imaging-prostate-15t 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/reproducibility-3d-1h-mr-spectroscopic-imaging-prostate-15t 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/reproducibility-3d-1h-mr-spectroscopic-imaging-prostate-15t 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/everolimus-postmenopausal-hormone-receptor-positive-advanced-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/everolimus-postmenopausal-hormone-receptor-positive-advanced-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/everolimus-postmenopausal-hormone-receptor-positive-advanced-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/peptides-targeting-estrogen-receptor-alpha-potential-applications-breast-cancer-treatment 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/peptides-targeting-estrogen-receptor-alpha-potential-applications-breast-cancer-treatment 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/peptides-targeting-estrogen-receptor-alpha-potential-applications-breast-cancer-treatment 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/axillary-recurrence-rate-breast-cancer-patients-negative-sentinel-lymph-node-biopsy-or-containing 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/axillary-recurrence-rate-breast-cancer-patients-negative-sentinel-lymph-node-biopsy-or-containing 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/axillary-recurrence-rate-breast-cancer-patients-negative-sentinel-lymph-node-biopsy-or-containing 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/cancer-cells-epithelial-mesenchymal-transition-and-tumor-propagating-cancer-stem-cells-distinct 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/cancer-cells-epithelial-mesenchymal-transition-and-tumor-propagating-cancer-stem-cells-distinct 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/cancer-cells-epithelial-mesenchymal-transition-and-tumor-propagating-cancer-stem-cells-distinct 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/localising-prostate-cancer-comparison-endorectal-magnetic-resonance-mr-imaging-and-3d-mr 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/localising-prostate-cancer-comparison-endorectal-magnetic-resonance-mr-imaging-and-3d-mr 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/localising-prostate-cancer-comparison-endorectal-magnetic-resonance-mr-imaging-and-3d-mr 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/role-farnesoid-x-receptor-fxr-process-differentiation-bone-marrow-stromal-cells-osteoblasts 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/role-farnesoid-x-receptor-fxr-process-differentiation-bone-marrow-stromal-cells-osteoblasts 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/role-farnesoid-x-receptor-fxr-process-differentiation-bone-marrow-stromal-cells-osteoblasts 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/best-supportive-care-early-palliative-care 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/best-supportive-care-early-palliative-care 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/best-supportive-care-early-palliative-care 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/short-course-chemotherapy-followed-concomitant-chemoradiotherapy-and-surgery-locally-advanced 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/short-course-chemotherapy-followed-concomitant-chemoradiotherapy-and-surgery-locally-advanced 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/short-course-chemotherapy-followed-concomitant-chemoradiotherapy-and-surgery-locally-advanced 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/relationship-between-heart-rate-variability-and-time-course-carcinoembryonic-antigen-colorectal 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/relationship-between-heart-rate-variability-and-time-course-carcinoembryonic-antigen-colorectal 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/relationship-between-heart-rate-variability-and-time-course-carcinoembryonic-antigen-colorectal 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/new-strategies-and-designs-pancreatic-cancer-research-consensus-guidelines-report-european-expert-0 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/new-strategies-and-designs-pancreatic-cancer-research-consensus-guidelines-report-european-expert-0 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/new-strategies-and-designs-pancreatic-cancer-research-consensus-guidelines-report-european-expert-0 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/randomized-phase-iiiii-trial-assessing-gemcitabinecarboplatin-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/randomized-phase-iiiii-trial-assessing-gemcitabinecarboplatin-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/randomized-phase-iiiii-trial-assessing-gemcitabinecarboplatin-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/rare-case-pancreatic-mass-due-accessory-spleen-when-eus-fna-not-enough 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/rare-case-pancreatic-mass-due-accessory-spleen-when-eus-fna-not-enough 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/rare-case-pancreatic-mass-due-accessory-spleen-when-eus-fna-not-enough 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/detection-and-characterization-tumor-changes-18f-fdg-pet-patient-monitoring-using-parametric 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/detection-and-characterization-tumor-changes-18f-fdg-pet-patient-monitoring-using-parametric 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/detection-and-characterization-tumor-changes-18f-fdg-pet-patient-monitoring-using-parametric 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/her2-positive-circulating-tumor-cells-breast-cancer 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/her2-positive-circulating-tumor-cells-breast-cancer 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/her2-positive-circulating-tumor-cells-breast-cancer 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/fine-tuning-van-nuys-prognostic-index-vnpi-2003-integrating-genomic-grade-index-ggi-new-tools 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/fine-tuning-van-nuys-prognostic-index-vnpi-2003-integrating-genomic-grade-index-ggi-new-tools 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/fine-tuning-van-nuys-prognostic-index-vnpi-2003-integrating-genomic-grade-index-ggi-new-tools 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/global-microrna-expression-profiling-identifies-mir-210-associated-tumor-proliferation-invasion-and 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/global-microrna-expression-profiling-identifies-mir-210-associated-tumor-proliferation-invasion-and 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/global-microrna-expression-profiling-identifies-mir-210-associated-tumor-proliferation-invasion-and 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/gene-profiling-assay-and-application-predictive-role-primary-therapy 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/gene-profiling-assay-and-application-predictive-role-primary-therapy 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/gene-profiling-assay-and-application-predictive-role-primary-therapy 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/largest-ever-dna-methylation-dataset-breast-cancer-completed 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/largest-ever-dna-methylation-dataset-breast-cancer-completed 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/largest-ever-dna-methylation-dataset-breast-cancer-completed 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/consistent-metagenes-cancer-expression-profiles-yield-agent-specific-predictors-chemotherapy 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/consistent-metagenes-cancer-expression-profiles-yield-agent-specific-predictors-chemotherapy 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/consistent-metagenes-cancer-expression-profiles-yield-agent-specific-predictors-chemotherapy 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/her2-and-top2a-predictive-markers-anthracycline-containing-chemotherapy-regimens-adjuvant-treatment 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/her2-and-top2a-predictive-markers-anthracycline-containing-chemotherapy-regimens-adjuvant-treatment 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/her2-and-top2a-predictive-markers-anthracycline-containing-chemotherapy-regimens-adjuvant-treatment 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/low-residual-proliferation-after-short-term-letrozole-therapy-early-predictive-marker-response-high 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/low-residual-proliferation-after-short-term-letrozole-therapy-early-predictive-marker-response-high 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/low-residual-proliferation-after-short-term-letrozole-therapy-early-predictive-marker-response-high 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/multiple-input-multiple-output-causal-strategies-gene-selection 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/multiple-input-multiple-output-causal-strategies-gene-selection 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/multiple-input-multiple-output-causal-strategies-gene-selection 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/dna-methylation-profiling-reveals-predominant-immune-component-breast-cancers 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/dna-methylation-profiling-reveals-predominant-immune-component-breast-cancers 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/dna-methylation-profiling-reveals-predominant-immune-component-breast-cancers 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/modeling-invasive-breast-cancer-growth-factors-propel-progression-her2-positive-premalignant 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/modeling-invasive-breast-cancer-growth-factors-propel-progression-her2-positive-premalignant 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/modeling-invasive-breast-cancer-growth-factors-propel-progression-her2-positive-premalignant 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/neoadjuvant-chemotherapy-and-targeted-therapies-promising-strategy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/neoadjuvant-chemotherapy-and-targeted-therapies-promising-strategy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/neoadjuvant-chemotherapy-and-targeted-therapies-promising-strategy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/international-expert-consensus-primary-systemic-therapy-management-early-breast-cancer-highlights 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/international-expert-consensus-primary-systemic-therapy-management-early-breast-cancer-highlights 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/international-expert-consensus-primary-systemic-therapy-management-early-breast-cancer-highlights 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/cardiovascular-side-effects-cancer-therapies-position-statement-heart-failure-association-european 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/cardiovascular-side-effects-cancer-therapies-position-statement-heart-failure-association-european 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/cardiovascular-side-effects-cancer-therapies-position-statement-heart-failure-association-european 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/motherhood-after-breast-cancer-searching-la-dolce-vita 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/motherhood-after-breast-cancer-searching-la-dolce-vita 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/motherhood-after-breast-cancer-searching-la-dolce-vita 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/neoadjuvant-anthracycline-and-trastuzumab-breast-cancer-concurrent-treatment-safe 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/neoadjuvant-anthracycline-and-trastuzumab-breast-cancer-concurrent-treatment-safe 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/neoadjuvant-anthracycline-and-trastuzumab-breast-cancer-concurrent-treatment-safe 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/multifactorial-approach-predicting-resistance-anthracyclines 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/multifactorial-approach-predicting-resistance-anthracyclines 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/multifactorial-approach-predicting-resistance-anthracyclines 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/role-multidisciplinary-team-breast-cancer-management-results-large-international-survey-involving 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/role-multidisciplinary-team-breast-cancer-management-results-large-international-survey-involving 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/role-multidisciplinary-team-breast-cancer-management-results-large-international-survey-involving 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/long-term-toxic-effects-adjuvant-chemotherapy-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/long-term-toxic-effects-adjuvant-chemotherapy-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/long-term-toxic-effects-adjuvant-chemotherapy-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/beyond-trastuzumab-new-treatment-options-her2-positive-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/beyond-trastuzumab-new-treatment-options-her2-positive-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/beyond-trastuzumab-new-treatment-options-her2-positive-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/her2-overexpressing-breast-cancer-time-cure-less-chemotherapy 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/her2-overexpressing-breast-cancer-time-cure-less-chemotherapy 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/her2-overexpressing-breast-cancer-time-cure-less-chemotherapy 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/improving-quality-life-after-breast-cancer-dealing-symptoms 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/improving-quality-life-after-breast-cancer-dealing-symptoms 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/improving-quality-life-after-breast-cancer-dealing-symptoms 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/patient-information-stem-cell-transplantation-perspective-health-care-professionals-survey-nurses 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/patient-information-stem-cell-transplantation-perspective-health-care-professionals-survey-nurses 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/patient-information-stem-cell-transplantation-perspective-health-care-professionals-survey-nurses 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/source-human-mesenchymal-stromal-cells-influences-their-tlr-profile-well-their-functional 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/source-human-mesenchymal-stromal-cells-influences-their-tlr-profile-well-their-functional 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/source-human-mesenchymal-stromal-cells-influences-their-tlr-profile-well-their-functional 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/non-hodgkin-s-lymphomas-major-breakthrough-immunotherapy 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/non-hodgkin-s-lymphomas-major-breakthrough-immunotherapy 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/non-hodgkin-s-lymphomas-major-breakthrough-immunotherapy 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/amd3100-disrupts-cross-talk-between-chronic-lymphocytic-leukemia-cells-and-mesenchymal-stromal-or 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/amd3100-disrupts-cross-talk-between-chronic-lymphocytic-leukemia-cells-and-mesenchymal-stromal-or 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/amd3100-disrupts-cross-talk-between-chronic-lymphocytic-leukemia-cells-and-mesenchymal-stromal-or 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/invasive-mechanical-ventilation-cancer-patients-prior-non-invasive-ventilation-poor-prognostic 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/invasive-mechanical-ventilation-cancer-patients-prior-non-invasive-ventilation-poor-prognostic 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/invasive-mechanical-ventilation-cancer-patients-prior-non-invasive-ventilation-poor-prognostic 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/c-erbb-3-expression-non-small-cell-lung-cancer-nsclc-patients-treated-erlotinib 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/c-erbb-3-expression-non-small-cell-lung-cancer-nsclc-patients-treated-erlotinib 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/c-erbb-3-expression-non-small-cell-lung-cancer-nsclc-patients-treated-erlotinib 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/febrile-neutropenia-emergency-department-cancer-hospital 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/febrile-neutropenia-emergency-department-cancer-hospital 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/febrile-neutropenia-emergency-department-cancer-hospital 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/prognostic-factors-stage-iii-non-small-cell-lung-cancer-review-conventional-metabolic-and-new 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/prognostic-factors-stage-iii-non-small-cell-lung-cancer-review-conventional-metabolic-and-new 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/prognostic-factors-stage-iii-non-small-cell-lung-cancer-review-conventional-metabolic-and-new 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/positron-emission-tomography-18f-fdg-and-cancer-response-chemotherapy 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/positron-emission-tomography-18f-fdg-and-cancer-response-chemotherapy 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/positron-emission-tomography-18f-fdg-and-cancer-response-chemotherapy 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/salvage-erlotinib-plus-bevacizumab-not-nsclc 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/salvage-erlotinib-plus-bevacizumab-not-nsclc 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/salvage-erlotinib-plus-bevacizumab-not-nsclc 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/rare-cause-superior-vena-cava-syndrome 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/rare-cause-superior-vena-cava-syndrome 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/rare-cause-superior-vena-cava-syndrome 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/validation-and-comparison-several-published-prognostic-systems-patients-small-cell-lung-cancer 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/validation-and-comparison-several-published-prognostic-systems-patients-small-cell-lung-cancer 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/validation-and-comparison-several-published-prognostic-systems-patients-small-cell-lung-cancer 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/pemetrexed-salvage-chemotherapy-nsclc-implementation-study 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/pemetrexed-salvage-chemotherapy-nsclc-implementation-study 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/pemetrexed-salvage-chemotherapy-nsclc-implementation-study 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/surrogate-markers-predicting-overall-survival-lung-cancer-elcwp-recommendations 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/surrogate-markers-predicting-overall-survival-lung-cancer-elcwp-recommendations 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/surrogate-markers-predicting-overall-survival-lung-cancer-elcwp-recommendations 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/treatment-trastuzumab-1-year-after-adjuvant-chemotherapy-patients-her2-positive-early-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/treatment-trastuzumab-1-year-after-adjuvant-chemotherapy-patients-her2-positive-early-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/treatment-trastuzumab-1-year-after-adjuvant-chemotherapy-patients-her2-positive-early-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/chemoprevention-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/chemoprevention-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/chemoprevention-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/prevention-and-management-major-side-effects-targeted-agents-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/prevention-and-management-major-side-effects-targeted-agents-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/prevention-and-management-major-side-effects-targeted-agents-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/multicentre-dose-escalating-study-cabazitaxel-xrp6258-combination-capecitabine-patients-metastatic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/multicentre-dose-escalating-study-cabazitaxel-xrp6258-combination-capecitabine-patients-metastatic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/multicentre-dose-escalating-study-cabazitaxel-xrp6258-combination-capecitabine-patients-metastatic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/lapatinib-ditosylate-expanding-therapeutic-options-receptor-tyrosine-protein-kinase-erbb-2-positive 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/lapatinib-ditosylate-expanding-therapeutic-options-receptor-tyrosine-protein-kinase-erbb-2-positive 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/lapatinib-ditosylate-expanding-therapeutic-options-receptor-tyrosine-protein-kinase-erbb-2-positive 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/recurrent-thyroid-cancer-molecular-based-therapeutic-breakthrough 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/recurrent-thyroid-cancer-molecular-based-therapeutic-breakthrough 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/recurrent-thyroid-cancer-molecular-based-therapeutic-breakthrough 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/maximising-duration-disease-control-metastatic-renal-cell-carcinoma-targeted-agents-expert 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/maximising-duration-disease-control-metastatic-renal-cell-carcinoma-targeted-agents-expert 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/maximising-duration-disease-control-metastatic-renal-cell-carcinoma-targeted-agents-expert 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/phase-2-trial-dasatinib-patients-advanced-her2-positive-andor-hormone-receptor-positive-breast 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/phase-2-trial-dasatinib-patients-advanced-her2-positive-andor-hormone-receptor-positive-breast 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/phase-2-trial-dasatinib-patients-advanced-her2-positive-andor-hormone-receptor-positive-breast 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/survival-benefit-eribulin-mesylate-heavily-pretreated-metastatic-breast-cancer-what-next 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/survival-benefit-eribulin-mesylate-heavily-pretreated-metastatic-breast-cancer-what-next 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/survival-benefit-eribulin-mesylate-heavily-pretreated-metastatic-breast-cancer-what-next 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/tyrp1-mrna-expression-melanoma-metastases-correlates-clinical-outcome 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/tyrp1-mrna-expression-melanoma-metastases-correlates-clinical-outcome 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/tyrp1-mrna-expression-melanoma-metastases-correlates-clinical-outcome 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/serial-fdg-petct-early-outcome-prediction-patients-metastatic-colorectal-cancer-undergoing 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/serial-fdg-petct-early-outcome-prediction-patients-metastatic-colorectal-cancer-undergoing 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/serial-fdg-petct-early-outcome-prediction-patients-metastatic-colorectal-cancer-undergoing 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/safety-and-pharmacokinetics-sorafenib-combined-capecitabine-patients-advanced-solid-tumors-results 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/safety-and-pharmacokinetics-sorafenib-combined-capecitabine-patients-advanced-solid-tumors-results 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/safety-and-pharmacokinetics-sorafenib-combined-capecitabine-patients-advanced-solid-tumors-results 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/treatment-metastatic-breast-cancer-state-art-subtypes-and-perspectives 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/treatment-metastatic-breast-cancer-state-art-subtypes-and-perspectives 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/treatment-metastatic-breast-cancer-state-art-subtypes-and-perspectives 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/phase-i-dose-escalation-study-novel-polo-kinase-inhibitor-volasertib-bi-6727-patients-advanced 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/phase-i-dose-escalation-study-novel-polo-kinase-inhibitor-volasertib-bi-6727-patients-advanced 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/phase-i-dose-escalation-study-novel-polo-kinase-inhibitor-volasertib-bi-6727-patients-advanced 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/milestones-use-chemotherapy-management-non-small-cell-lung-cancer-nsclc 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/milestones-use-chemotherapy-management-non-small-cell-lung-cancer-nsclc 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/milestones-use-chemotherapy-management-non-small-cell-lung-cancer-nsclc 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/observational-efficacy-and-safety-analysis-treatment-acute-invasive-aspergillosis-using 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/observational-efficacy-and-safety-analysis-treatment-acute-invasive-aspergillosis-using 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/observational-efficacy-and-safety-analysis-treatment-acute-invasive-aspergillosis-using 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/parathyroid-carcinoma-review-three-illustrative-cases 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/parathyroid-carcinoma-review-three-illustrative-cases 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/parathyroid-carcinoma-review-three-illustrative-cases 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/uvular-and-tonsillar-pillar-mucosal-necrosis-cause-severe-sore-throat-after-orotracheal-intubation 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/uvular-and-tonsillar-pillar-mucosal-necrosis-cause-severe-sore-throat-after-orotracheal-intubation 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/uvular-and-tonsillar-pillar-mucosal-necrosis-cause-severe-sore-throat-after-orotracheal-intubation 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/single-access-transumbilical-laparoscopic-appendectomy-and-cholecystectomy-using-new-curved 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/single-access-transumbilical-laparoscopic-appendectomy-and-cholecystectomy-using-new-curved 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/single-access-transumbilical-laparoscopic-appendectomy-and-cholecystectomy-using-new-curved 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/how-much-residents-distress-detection-performance-during-clinical-round-related-their 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/how-much-residents-distress-detection-performance-during-clinical-round-related-their 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/how-much-residents-distress-detection-performance-during-clinical-round-related-their 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/pattern-care-locally-advanced-breast-cancer-focus-local-therapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/pattern-care-locally-advanced-breast-cancer-focus-local-therapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/pattern-care-locally-advanced-breast-cancer-focus-local-therapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/accuracy-api-campy-system-vitek-2-neisseria-haemophilus-card-and-matrix-assisted-laser-desorption 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/accuracy-api-campy-system-vitek-2-neisseria-haemophilus-card-and-matrix-assisted-laser-desorption 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/accuracy-api-campy-system-vitek-2-neisseria-haemophilus-card-and-matrix-assisted-laser-desorption 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/phase-ii-study-efficacy-and-safety-amg-102-patients-metastatic-renal-cell-carcinoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/phase-ii-study-efficacy-and-safety-amg-102-patients-metastatic-renal-cell-carcinoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/phase-ii-study-efficacy-and-safety-amg-102-patients-metastatic-renal-cell-carcinoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/signaling-human-melanocortin-1-receptor-erk1-and-erk2-mitogen-activated-protein-kinases-involves 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/signaling-human-melanocortin-1-receptor-erk1-and-erk2-mitogen-activated-protein-kinases-involves 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/signaling-human-melanocortin-1-receptor-erk1-and-erk2-mitogen-activated-protein-kinases-involves 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/prognostic-value-serial-blood-s100b-determinations-stage-iib-iii-melanoma-patients-corollary-study 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/prognostic-value-serial-blood-s100b-determinations-stage-iib-iii-melanoma-patients-corollary-study 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/prognostic-value-serial-blood-s100b-determinations-stage-iib-iii-melanoma-patients-corollary-study 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/increased-nerve-density-deep-infiltrating-endometriotic-nodules 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/increased-nerve-density-deep-infiltrating-endometriotic-nodules 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/increased-nerve-density-deep-infiltrating-endometriotic-nodules 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/small-cell-carcinoma-esophagus-multicentre-rare-cancer-network-study 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/small-cell-carcinoma-esophagus-multicentre-rare-cancer-network-study 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/small-cell-carcinoma-esophagus-multicentre-rare-cancer-network-study 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/phase-1-study-bms-275183-novel-oral-analogue-paclitaxel-given-daily-schedule-patients-advanced 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/phase-1-study-bms-275183-novel-oral-analogue-paclitaxel-given-daily-schedule-patients-advanced 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/phase-1-study-bms-275183-novel-oral-analogue-paclitaxel-given-daily-schedule-patients-advanced 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/validation-institut-curie-simplified-prognostic-score-breast-cancer-meningeal-carcinomatosis 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/validation-institut-curie-simplified-prognostic-score-breast-cancer-meningeal-carcinomatosis 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/validation-institut-curie-simplified-prognostic-score-breast-cancer-meningeal-carcinomatosis 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/prevention-febrile-neutropenia-chemotherapy-treated-cancer-patients-pegylated-versus-standard-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/prevention-febrile-neutropenia-chemotherapy-treated-cancer-patients-pegylated-versus-standard-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/prevention-febrile-neutropenia-chemotherapy-treated-cancer-patients-pegylated-versus-standard-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/inaugural-bilateral-aspergillus-endophthalmitis-seriously-immunocompromised-patient 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/inaugural-bilateral-aspergillus-endophthalmitis-seriously-immunocompromised-patient 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/inaugural-bilateral-aspergillus-endophthalmitis-seriously-immunocompromised-patient 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/febrile-neutropenia-critical-review-initial-management 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/febrile-neutropenia-critical-review-initial-management 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/febrile-neutropenia-critical-review-initial-management 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/predicting-febrile-neutropenic-patients-low-risk-using-mascc-score-does-bacteremia-matter 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/predicting-febrile-neutropenic-patients-low-risk-using-mascc-score-does-bacteremia-matter 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/predicting-febrile-neutropenic-patients-low-risk-using-mascc-score-does-bacteremia-matter 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/valproate-doxorubicin-promising-therapy-progressing-mesothelioma-phase-ii-study 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/valproate-doxorubicin-promising-therapy-progressing-mesothelioma-phase-ii-study 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/valproate-doxorubicin-promising-therapy-progressing-mesothelioma-phase-ii-study 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/rapid-simple-and-reproducible-method-isolation-mesenchymal-stromal-cells-wharton-s-jelly-without 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/rapid-simple-and-reproducible-method-isolation-mesenchymal-stromal-cells-wharton-s-jelly-without 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/rapid-simple-and-reproducible-method-isolation-mesenchymal-stromal-cells-wharton-s-jelly-without 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/indications-and-complications-pelvic-lymph-node-dissection-prostate-cancer-accuracy-available 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/indications-and-complications-pelvic-lymph-node-dissection-prostate-cancer-accuracy-available 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/indications-and-complications-pelvic-lymph-node-dissection-prostate-cancer-accuracy-available 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/discriminating-value-hr-pqct-fractures-women-similar-frax-scores-substudy-frisbee-cohort 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/discriminating-value-hr-pqct-fractures-women-similar-frax-scores-substudy-frisbee-cohort 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/discriminating-value-hr-pqct-fractures-women-similar-frax-scores-substudy-frisbee-cohort 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/de-intensifying-radiation-therapy-her-2-positive-breast-cancer-boost-or-not-boost 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/de-intensifying-radiation-therapy-her-2-positive-breast-cancer-boost-or-not-boost 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/de-intensifying-radiation-therapy-her-2-positive-breast-cancer-boost-or-not-boost 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/fat-density-novel-prognostic-marker-patients-esophageal-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/fat-density-novel-prognostic-marker-patients-esophageal-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/fat-density-novel-prognostic-marker-patients-esophageal-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/endocrine-therapy-based-treatments-hormone-receptor-positiveher2-negative-advanced-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/endocrine-therapy-based-treatments-hormone-receptor-positiveher2-negative-advanced-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/endocrine-therapy-based-treatments-hormone-receptor-positiveher2-negative-advanced-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/risk-relapse-after-anti-pd1-discontinuation-patients-hodgkin-lymphoma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/risk-relapse-after-anti-pd1-discontinuation-patients-hodgkin-lymphoma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/risk-relapse-after-anti-pd1-discontinuation-patients-hodgkin-lymphoma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/phase-1-dose-escalation-study-evaluate-safety-pharmacokinetics-and-pharmacodynamics-asidna-first 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/phase-1-dose-escalation-study-evaluate-safety-pharmacokinetics-and-pharmacodynamics-asidna-first 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/phase-1-dose-escalation-study-evaluate-safety-pharmacokinetics-and-pharmacodynamics-asidna-first 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/clinical-outcome-surgically-treated-leiomyosarcoma-extremities-retrospective-overview 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/clinical-outcome-surgically-treated-leiomyosarcoma-extremities-retrospective-overview 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/clinical-outcome-surgically-treated-leiomyosarcoma-extremities-retrospective-overview 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/vessel-morphology-depicted-three-dimensional-power-doppler-ultrasound-second-stage-test-difficult 2020-09-14T07:00:05+02:00 0.5 https://bordet.makemeweb.dev/en/oncological-care-organisation-during-covid-19-outbreak 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/oncological-care-organisation-during-covid-19-outbreak 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/oncological-care-organisation-during-covid-19-outbreak 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/care-process-patient-receiving-car-t-cell-therapy-guidelines-francophone-society-bone-marrow 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/care-process-patient-receiving-car-t-cell-therapy-guidelines-francophone-society-bone-marrow 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/care-process-patient-receiving-car-t-cell-therapy-guidelines-francophone-society-bone-marrow 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/are-we-respecting-older-patients-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/are-we-respecting-older-patients-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/are-we-respecting-older-patients-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/application-esmo-magnitude-clinical-benefit-scale-v11-field-early-breast-cancer-therapies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/application-esmo-magnitude-clinical-benefit-scale-v11-field-early-breast-cancer-therapies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/application-esmo-magnitude-clinical-benefit-scale-v11-field-early-breast-cancer-therapies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/adenomatoid-tumor-skin-differential-diagnosis-umbilical-erythematous-plaque 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/adenomatoid-tumor-skin-differential-diagnosis-umbilical-erythematous-plaque 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/adenomatoid-tumor-skin-differential-diagnosis-umbilical-erythematous-plaque 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/randomized-placebo-controlled-phase-ii-trial-evaluating-exemestane-or-without-enzalutamide-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/randomized-placebo-controlled-phase-ii-trial-evaluating-exemestane-or-without-enzalutamide-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/randomized-placebo-controlled-phase-ii-trial-evaluating-exemestane-or-without-enzalutamide-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/tolerability-and-toxicity-trastuzumab-or-trastuzumablapatinib-older-patients-sub-analysis-altto 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/tolerability-and-toxicity-trastuzumab-or-trastuzumablapatinib-older-patients-sub-analysis-altto 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/tolerability-and-toxicity-trastuzumab-or-trastuzumablapatinib-older-patients-sub-analysis-altto 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/meta-analysis-induction-chemotherapy-locally-advanced-nasopharyngeal-carcinoma 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/meta-analysis-induction-chemotherapy-locally-advanced-nasopharyngeal-carcinoma 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/meta-analysis-induction-chemotherapy-locally-advanced-nasopharyngeal-carcinoma 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/identification-acute-myeloid-leukemia-bone-marrow-circulating-micrornas 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/identification-acute-myeloid-leukemia-bone-marrow-circulating-micrornas 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/identification-acute-myeloid-leukemia-bone-marrow-circulating-micrornas 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/importance-crosstalk-between-chronic-lymphocytic-leukemia-cells-and-stromal-microenvironment-direct 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/importance-crosstalk-between-chronic-lymphocytic-leukemia-cells-and-stromal-microenvironment-direct 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/importance-crosstalk-between-chronic-lymphocytic-leukemia-cells-and-stromal-microenvironment-direct 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/impact-solid-cancer-hospital-mortality-overall-and-among-different-subgroups-patients-covid-19 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/impact-solid-cancer-hospital-mortality-overall-and-among-different-subgroups-patients-covid-19 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/impact-solid-cancer-hospital-mortality-overall-and-among-different-subgroups-patients-covid-19 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/quality-life-patients-hypoparathyroidism-after-treatment-thyroid-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/quality-life-patients-hypoparathyroidism-after-treatment-thyroid-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/quality-life-patients-hypoparathyroidism-after-treatment-thyroid-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/acute-respiratory-failure-outcomes-patients-hematologic-malignancies-and-hematopoietic-cell 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/acute-respiratory-failure-outcomes-patients-hematologic-malignancies-and-hematopoietic-cell 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/acute-respiratory-failure-outcomes-patients-hematologic-malignancies-and-hematopoietic-cell 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/characterization-stromal-tumor-infiltrating-lymphocytes-and-genomic-alterations-metastatic-lobular 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/characterization-stromal-tumor-infiltrating-lymphocytes-and-genomic-alterations-metastatic-lobular 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/characterization-stromal-tumor-infiltrating-lymphocytes-and-genomic-alterations-metastatic-lobular 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/phase-1b-study-evaluating-effect-elacestrant-treatment-estrogen-receptor-availability-and-estradiol 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/phase-1b-study-evaluating-effect-elacestrant-treatment-estrogen-receptor-availability-and-estradiol 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/phase-1b-study-evaluating-effect-elacestrant-treatment-estrogen-receptor-availability-and-estradiol 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/management-early-breast-cancer-patients-bearing-germline-brca-mutations 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/management-early-breast-cancer-patients-bearing-germline-brca-mutations 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/management-early-breast-cancer-patients-bearing-germline-brca-mutations 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/adverse-events-reporting-stage-iii-nsclc-trials-investigating-surgery-and-radiotherapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/adverse-events-reporting-stage-iii-nsclc-trials-investigating-surgery-and-radiotherapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/adverse-events-reporting-stage-iii-nsclc-trials-investigating-surgery-and-radiotherapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/combined-liver-resection-and-cytoreductive-surgery-hipec-metastatic-colorectal-cancer-results 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/combined-liver-resection-and-cytoreductive-surgery-hipec-metastatic-colorectal-cancer-results 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/combined-liver-resection-and-cytoreductive-surgery-hipec-metastatic-colorectal-cancer-results 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/reply-letter-editor-esmo-magnitude-clinical-benefit-scaling-tool-theory-practice-hartmann-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/reply-letter-editor-esmo-magnitude-clinical-benefit-scaling-tool-theory-practice-hartmann-and-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/reply-letter-editor-esmo-magnitude-clinical-benefit-scaling-tool-theory-practice-hartmann-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/prognostic-value-pace-tumor-progression-assessed-serial-18-f-fdg-petct-scan-and-liquid-biopsy 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/prognostic-value-pace-tumor-progression-assessed-serial-18-f-fdg-petct-scan-and-liquid-biopsy 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/prognostic-value-pace-tumor-progression-assessed-serial-18-f-fdg-petct-scan-and-liquid-biopsy 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/breast-cancer-subtypes-implications-treatment-and-survival-patients-africa-prospective-cohort-study 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/breast-cancer-subtypes-implications-treatment-and-survival-patients-africa-prospective-cohort-study 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/breast-cancer-subtypes-implications-treatment-and-survival-patients-africa-prospective-cohort-study 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/intratumoral-transcriptome-heterogeneity-associated-patient-prognosis-and-sidedness-patients 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/intratumoral-transcriptome-heterogeneity-associated-patient-prognosis-and-sidedness-patients 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/intratumoral-transcriptome-heterogeneity-associated-patient-prognosis-and-sidedness-patients 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/systematic-review-neoadjuvant-therapy-immune-checkpoint-inhibitors-radical-cystectomy-where-do-we 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/systematic-review-neoadjuvant-therapy-immune-checkpoint-inhibitors-radical-cystectomy-where-do-we 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/systematic-review-neoadjuvant-therapy-immune-checkpoint-inhibitors-radical-cystectomy-where-do-we 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/reimagining-global-oncology-clinical-trials-postpandemic-era-call-arms 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/reimagining-global-oncology-clinical-trials-postpandemic-era-call-arms 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/reimagining-global-oncology-clinical-trials-postpandemic-era-call-arms 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/impact-bone-marrow-mir-21-expression-acute-myeloid-leukemia-t-lymphocyte-fragility-and-dysfunction 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/impact-bone-marrow-mir-21-expression-acute-myeloid-leukemia-t-lymphocyte-fragility-and-dysfunction 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/impact-bone-marrow-mir-21-expression-acute-myeloid-leukemia-t-lymphocyte-fragility-and-dysfunction 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/mortality-patients-cancer-and-coronavirus-disease-2019-systematic-review-and-pooled-analysis-52 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/mortality-patients-cancer-and-coronavirus-disease-2019-systematic-review-and-pooled-analysis-52 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/mortality-patients-cancer-and-coronavirus-disease-2019-systematic-review-and-pooled-analysis-52 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/computer-assisted-prescription-future-nutrition-care 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/computer-assisted-prescription-future-nutrition-care 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/computer-assisted-prescription-future-nutrition-care 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/quality-life-trajectories-breast-cancer-patients-updated-analysis-5-years-after-diagnosis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/quality-life-trajectories-breast-cancer-patients-updated-analysis-5-years-after-diagnosis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/quality-life-trajectories-breast-cancer-patients-updated-analysis-5-years-after-diagnosis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/covid-19-and-male-susceptibility-role-ace2-tmprss2-and-androgen-receptor 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/covid-19-and-male-susceptibility-role-ace2-tmprss2-and-androgen-receptor 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/covid-19-and-male-susceptibility-role-ace2-tmprss2-and-androgen-receptor 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/myeloid-tumor-necrosis-factor-and-heme-oxygenase-1-regulate-progression-colorectal-liver-metastases 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/myeloid-tumor-necrosis-factor-and-heme-oxygenase-1-regulate-progression-colorectal-liver-metastases 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/myeloid-tumor-necrosis-factor-and-heme-oxygenase-1-regulate-progression-colorectal-liver-metastases 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/external-validation-multiparametric-magnetic-resonance-imaging-based-nomogram-prediction 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/external-validation-multiparametric-magnetic-resonance-imaging-based-nomogram-prediction 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/external-validation-multiparametric-magnetic-resonance-imaging-based-nomogram-prediction 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/which-place-thoracic-surgery-2020-introduction-thematic-series 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/which-place-thoracic-surgery-2020-introduction-thematic-series 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/which-place-thoracic-surgery-2020-introduction-thematic-series 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/laparoscopic-transperitoneal-pudendal-nerve-and-artery-release-pudendal-entrapment-syndrome 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/laparoscopic-transperitoneal-pudendal-nerve-and-artery-release-pudendal-entrapment-syndrome 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/laparoscopic-transperitoneal-pudendal-nerve-and-artery-release-pudendal-entrapment-syndrome 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/stratifying-patients-intermediate-risk-prostate-cancer-validation-new-model-based-mri-parameters 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/stratifying-patients-intermediate-risk-prostate-cancer-validation-new-model-based-mri-parameters 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/stratifying-patients-intermediate-risk-prostate-cancer-validation-new-model-based-mri-parameters 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/postoperative-c-reactive-protein-kinetics-predict-postoperative-complications-patients-treated 2020-10-26T07:00:05+01:00 0.5 https://bordet.makemeweb.dev/fr/159p-clinical-landscape-central-nervous-system-cns-involvement-metastatic-triple-negative-breast 2020-10-26T07:00:05+01:00 0.5 https://bordet.makemeweb.dev/en/131i-metaiodobenzylguanidine-and-peptide-receptor-radionuclide-therapy-pheochromocytoma-and 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/131i-metaiodobenzylguanidine-and-peptide-receptor-radionuclide-therapy-pheochromocytoma-and 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/131i-metaiodobenzylguanidine-and-peptide-receptor-radionuclide-therapy-pheochromocytoma-and 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/safety-and-efficacy-photobiomodulation-therapy-oncology-systematic-review 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/safety-and-efficacy-photobiomodulation-therapy-oncology-systematic-review 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/safety-and-efficacy-photobiomodulation-therapy-oncology-systematic-review 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/antitumor-activity-lurbinectedin-second-line-small-cell-lung-cancer-patients-who-are-candidates-re 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/antitumor-activity-lurbinectedin-second-line-small-cell-lung-cancer-patients-who-are-candidates-re 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/antitumor-activity-lurbinectedin-second-line-small-cell-lung-cancer-patients-who-are-candidates-re 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/endocrine-tumors-rare-tumors 2020-11-02T07:00:04+01:00 0.5 https://bordet.makemeweb.dev/en/genomic-aberrations-and-late-recurrence-postmenopausal-women-hormone-receptor-positive-early-breast 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/genomic-aberrations-and-late-recurrence-postmenopausal-women-hormone-receptor-positive-early-breast 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/genomic-aberrations-and-late-recurrence-postmenopausal-women-hormone-receptor-positive-early-breast 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/multikinase-inhibitors-treatment-radioiodine-refractory-thyroid-cancer-what-have-we-learned-real 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/multikinase-inhibitors-treatment-radioiodine-refractory-thyroid-cancer-what-have-we-learned-real 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/multikinase-inhibitors-treatment-radioiodine-refractory-thyroid-cancer-what-have-we-learned-real 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/platelet-lymphocyte-ratio-correlated-delay-feeding-resumption-following-transhiatal-esophagectomy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/platelet-lymphocyte-ratio-correlated-delay-feeding-resumption-following-transhiatal-esophagectomy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/platelet-lymphocyte-ratio-correlated-delay-feeding-resumption-following-transhiatal-esophagectomy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/metaplastic-spiradenocarcinoma-report-two-cases-sarcomatous-differentiation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/metaplastic-spiradenocarcinoma-report-two-cases-sarcomatous-differentiation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/metaplastic-spiradenocarcinoma-report-two-cases-sarcomatous-differentiation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/road-map-safe-and-well-designed-de-escalation-trials-systemic-adjuvant-therapy-solid-tumors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/road-map-safe-and-well-designed-de-escalation-trials-systemic-adjuvant-therapy-solid-tumors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/road-map-safe-and-well-designed-de-escalation-trials-systemic-adjuvant-therapy-solid-tumors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/erratum-krayem-m-et-al-kinome-profiling-predict-sensitivity-mapk-inhibition-melanoma-and-provide 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/erratum-krayem-m-et-al-kinome-profiling-predict-sensitivity-mapk-inhibition-melanoma-and-provide 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/erratum-krayem-m-et-al-kinome-profiling-predict-sensitivity-mapk-inhibition-melanoma-and-provide 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/abemaciclib-third-cdk-46-inhibitor-treatment-hormone-receptor-positive-human-epidermal-growth 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/abemaciclib-third-cdk-46-inhibitor-treatment-hormone-receptor-positive-human-epidermal-growth 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/abemaciclib-third-cdk-46-inhibitor-treatment-hormone-receptor-positive-human-epidermal-growth 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/digital-analysis-distant-and-cancer-associated-mammary-adipocytes 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/digital-analysis-distant-and-cancer-associated-mammary-adipocytes 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/digital-analysis-distant-and-cancer-associated-mammary-adipocytes 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/inferior-epigastric-artery-lymph-nodes-pathway-systemic-dissemination-peritoneal-carcinomatosis 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/inferior-epigastric-artery-lymph-nodes-pathway-systemic-dissemination-peritoneal-carcinomatosis 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/inferior-epigastric-artery-lymph-nodes-pathway-systemic-dissemination-peritoneal-carcinomatosis 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/reply-s-narod-et-al 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/reply-s-narod-et-al 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/reply-s-narod-et-al 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/treatment-algorithm-patients-ovarian-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/treatment-algorithm-patients-ovarian-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/treatment-algorithm-patients-ovarian-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/can-success-immunotherapy-metastatic-urothelial-bladder-carcinoma-be-replicated-neoadjuvant-setting 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/can-success-immunotherapy-metastatic-urothelial-bladder-carcinoma-be-replicated-neoadjuvant-setting 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/can-success-immunotherapy-metastatic-urothelial-bladder-carcinoma-be-replicated-neoadjuvant-setting 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/european-registry-hidradenitis-suppurativa-state-play 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/european-registry-hidradenitis-suppurativa-state-play 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/european-registry-hidradenitis-suppurativa-state-play 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/vcam-1-target-non-invasive-imaging-detection-atherosclerotic-plaques 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/vcam-1-target-non-invasive-imaging-detection-atherosclerotic-plaques 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/vcam-1-target-non-invasive-imaging-detection-atherosclerotic-plaques 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/effect-body-mass-index-response-neo-adjuvant-therapy-her2-positive-breast-cancer-exploratory 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/effect-body-mass-index-response-neo-adjuvant-therapy-her2-positive-breast-cancer-exploratory 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/effect-body-mass-index-response-neo-adjuvant-therapy-her2-positive-breast-cancer-exploratory 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/stat3-activation-her2-positive-breast-cancers-analysis-data-large-prospective-trial 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/stat3-activation-her2-positive-breast-cancers-analysis-data-large-prospective-trial 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/stat3-activation-her2-positive-breast-cancers-analysis-data-large-prospective-trial 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/delayed-emergence-anesthesia-what-we-know-and-how-we-act 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/delayed-emergence-anesthesia-what-we-know-and-how-we-act 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/delayed-emergence-anesthesia-what-we-know-and-how-we-act 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/selective-oral-mek12-inhibitor-pimasertib-phase-i-trial-patients-advanced-solid-tumors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/selective-oral-mek12-inhibitor-pimasertib-phase-i-trial-patients-advanced-solid-tumors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/selective-oral-mek12-inhibitor-pimasertib-phase-i-trial-patients-advanced-solid-tumors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/improved-sequencing-based-bioinformatics-pipeline-track-distribution-and-clonal-architecture 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/improved-sequencing-based-bioinformatics-pipeline-track-distribution-and-clonal-architecture 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/improved-sequencing-based-bioinformatics-pipeline-track-distribution-and-clonal-architecture 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/diagnosis-pathophysiology-and-treatment-sirt-induced-gastroduodenal-ulcers-systematic-literature 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/diagnosis-pathophysiology-and-treatment-sirt-induced-gastroduodenal-ulcers-systematic-literature 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/diagnosis-pathophysiology-and-treatment-sirt-induced-gastroduodenal-ulcers-systematic-literature 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/clinical-trial-evidence-supporting-us-food-and-drug-administration-approval-novel-cancer-therapies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/clinical-trial-evidence-supporting-us-food-and-drug-administration-approval-novel-cancer-therapies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/clinical-trial-evidence-supporting-us-food-and-drug-administration-approval-novel-cancer-therapies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/validation-externe-du-nomogramme-base-sur-l-imagerie-par-resonance-magnetique-predisant-le-risque-d 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/validation-externe-du-nomogramme-base-sur-l-imagerie-par-resonance-magnetique-predisant-le-risque-d 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/validation-externe-du-nomogramme-base-sur-l-imagerie-par-resonance-magnetique-predisant-le-risque-d 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/baseline-plasma-levels-soluble-pd-1-pd-l1-and-btn3a1-predict-response-nivolumab-treatment-patients 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/baseline-plasma-levels-soluble-pd-1-pd-l1-and-btn3a1-predict-response-nivolumab-treatment-patients 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/baseline-plasma-levels-soluble-pd-1-pd-l1-and-btn3a1-predict-response-nivolumab-treatment-patients 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/quality-assessment-car-t-cell-activity-recommendations-francophone-society-bone-marrow 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/quality-assessment-car-t-cell-activity-recommendations-francophone-society-bone-marrow 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/quality-assessment-car-t-cell-activity-recommendations-francophone-society-bone-marrow 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/implications-venous-thromboembolism-gwas-reported-genetic-makeup-clinical-outcome-ovarian-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/implications-venous-thromboembolism-gwas-reported-genetic-makeup-clinical-outcome-ovarian-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/implications-venous-thromboembolism-gwas-reported-genetic-makeup-clinical-outcome-ovarian-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/role-radiotherapy-management-brain-metastases-nsclc-decision-criteria-clinical-routine 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/role-radiotherapy-management-brain-metastases-nsclc-decision-criteria-clinical-routine 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/role-radiotherapy-management-brain-metastases-nsclc-decision-criteria-clinical-routine 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/efficacy-dyadic-intervention-improve-communication-between-patients-cancer-and-their-caregivers 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/efficacy-dyadic-intervention-improve-communication-between-patients-cancer-and-their-caregivers 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/efficacy-dyadic-intervention-improve-communication-between-patients-cancer-and-their-caregivers 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/bratislava-statement-consensus-recommendations-improving-pancreatic-cancer-care 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/bratislava-statement-consensus-recommendations-improving-pancreatic-cancer-care 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/bratislava-statement-consensus-recommendations-improving-pancreatic-cancer-care 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/absence-residual-fluorescence-surgical-bed-near-infrared-fluorescence-imaging-predicts-negative 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/absence-residual-fluorescence-surgical-bed-near-infrared-fluorescence-imaging-predicts-negative 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/absence-residual-fluorescence-surgical-bed-near-infrared-fluorescence-imaging-predicts-negative 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/pd-1-protein-and-gene-expression-prognostic-factors-early-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/pd-1-protein-and-gene-expression-prognostic-factors-early-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/pd-1-protein-and-gene-expression-prognostic-factors-early-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/survival-and-treatment-outcome-head-and-neck-cancer-patients-pulmonary-oligometastases 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/survival-and-treatment-outcome-head-and-neck-cancer-patients-pulmonary-oligometastases 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/survival-and-treatment-outcome-head-and-neck-cancer-patients-pulmonary-oligometastases 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/prognostic-role-distant-disease-free-interval-completion-adjuvant-trastuzumab-her2-positive-early 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/prognostic-role-distant-disease-free-interval-completion-adjuvant-trastuzumab-her2-positive-early 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/prognostic-role-distant-disease-free-interval-completion-adjuvant-trastuzumab-her2-positive-early 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/le-delais-pour-une-prostatectomie-radicale-n-influence-pas-le-resultat-ontologique-etude-d-une 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/le-delais-pour-une-prostatectomie-radicale-n-influence-pas-le-resultat-ontologique-etude-d-une 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/le-delais-pour-une-prostatectomie-radicale-n-influence-pas-le-resultat-ontologique-etude-d-une 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/excision-repair-cross-complementation-group-1-single-nucleotide-polymorphisms-and-nivolumab 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/excision-repair-cross-complementation-group-1-single-nucleotide-polymorphisms-and-nivolumab 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/excision-repair-cross-complementation-group-1-single-nucleotide-polymorphisms-and-nivolumab 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/pudendal-nerve-entrapment-and-recurrent-urinary-tract-infection-there-link 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/pudendal-nerve-entrapment-and-recurrent-urinary-tract-infection-there-link 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/pudendal-nerve-entrapment-and-recurrent-urinary-tract-infection-there-link 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/european-cancer-organisation-essential-requirements-quality-cancer-care-erqcc-lung-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/european-cancer-organisation-essential-requirements-quality-cancer-care-erqcc-lung-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/european-cancer-organisation-essential-requirements-quality-cancer-care-erqcc-lung-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/atezolizumab-metastatic-triple-negative-breast-cancer-impassion130-and-131-trials-how-explain 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/atezolizumab-metastatic-triple-negative-breast-cancer-impassion130-and-131-trials-how-explain 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/atezolizumab-metastatic-triple-negative-breast-cancer-impassion130-and-131-trials-how-explain 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/impact-early-icu-admission-critically-ill-cancer-patients-post-hoc-analysis-prospective-multicenter 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/impact-early-icu-admission-critically-ill-cancer-patients-post-hoc-analysis-prospective-multicenter 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/impact-early-icu-admission-critically-ill-cancer-patients-post-hoc-analysis-prospective-multicenter 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/does-antibiotic-use-explain-discrepancy-urolithiasis-prevalence-between-countries 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/does-antibiotic-use-explain-discrepancy-urolithiasis-prevalence-between-countries 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/does-antibiotic-use-explain-discrepancy-urolithiasis-prevalence-between-countries 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/development-staffing-workload-and-infrastructure-member-departments-european-organisation-research 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/development-staffing-workload-and-infrastructure-member-departments-european-organisation-research 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/development-staffing-workload-and-infrastructure-member-departments-european-organisation-research 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/genomic-and-transcriptomic-correlates-richter-transformation-chronic-lymphocytic-leukemia 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/genomic-and-transcriptomic-correlates-richter-transformation-chronic-lymphocytic-leukemia 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/genomic-and-transcriptomic-correlates-richter-transformation-chronic-lymphocytic-leukemia 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/unplanned-hospitalizations-older-patients-cancer-occurrence-and-predictive-factors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/unplanned-hospitalizations-older-patients-cancer-occurrence-and-predictive-factors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/unplanned-hospitalizations-older-patients-cancer-occurrence-and-predictive-factors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/selective-oral-mek12-inhibitor-pimasertib-metastatic-melanoma-antitumor-activity-phase-i-dose 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/selective-oral-mek12-inhibitor-pimasertib-metastatic-melanoma-antitumor-activity-phase-i-dose 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/selective-oral-mek12-inhibitor-pimasertib-metastatic-melanoma-antitumor-activity-phase-i-dose 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/cdk46-inhibition-hr-positive-early-breast-cancer-are-we-putting-all-eggs-one-basket 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/cdk46-inhibition-hr-positive-early-breast-cancer-are-we-putting-all-eggs-one-basket 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/cdk46-inhibition-hr-positive-early-breast-cancer-are-we-putting-all-eggs-one-basket 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/healthcare-use-and-costs-early-breast-cancer-patient-level-data-analysis-according-stage-and-breast 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/healthcare-use-and-costs-early-breast-cancer-patient-level-data-analysis-according-stage-and-breast 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/healthcare-use-and-costs-early-breast-cancer-patient-level-data-analysis-according-stage-and-breast 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/metascoring-hidradenitis-suppurativa 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/metascoring-hidradenitis-suppurativa 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/metascoring-hidradenitis-suppurativa 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/first-man-phase-1-study-dna-dependent-protein-kinase-inhibitor-peposertib-formerly-m3814-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/first-man-phase-1-study-dna-dependent-protein-kinase-inhibitor-peposertib-formerly-m3814-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/first-man-phase-1-study-dna-dependent-protein-kinase-inhibitor-peposertib-formerly-m3814-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/postoperative-c-reactive-protein-kinetics-predict-postoperative-complications-patients-treated 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/postoperative-c-reactive-protein-kinetics-predict-postoperative-complications-patients-treated-0 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/postoperative-c-reactive-protein-kinetics-predict-postoperative-complications-patients-treated 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/targeting-ctla-4-cancer-it-ideal-companion-pd-1-blockade-immunotherapy-combinations 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/targeting-ctla-4-cancer-it-ideal-companion-pd-1-blockade-immunotherapy-combinations 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/targeting-ctla-4-cancer-it-ideal-companion-pd-1-blockade-immunotherapy-combinations 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/lymphoscintigraphic-bilateral-disease-patients-clinically-unilateral-primary-lower-limb-lymphedemas 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/lymphoscintigraphic-bilateral-disease-patients-clinically-unilateral-primary-lower-limb-lymphedemas 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/lymphoscintigraphic-bilateral-disease-patients-clinically-unilateral-primary-lower-limb-lymphedemas 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/impact-arts-oncological-outcomes-young-breast-cancer-survivors 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/impact-arts-oncological-outcomes-young-breast-cancer-survivors 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/impact-arts-oncological-outcomes-young-breast-cancer-survivors 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/pudendal-nerve-release-lower-urinary-tract-symptoms-young-males 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/pudendal-nerve-release-lower-urinary-tract-symptoms-young-males 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/pudendal-nerve-release-lower-urinary-tract-symptoms-young-males 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/survival-impact-and-cost-effectiveness-multidisciplinary-tumor-board-breast-cancer-mozambique-sub 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/survival-impact-and-cost-effectiveness-multidisciplinary-tumor-board-breast-cancer-mozambique-sub 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/survival-impact-and-cost-effectiveness-multidisciplinary-tumor-board-breast-cancer-mozambique-sub 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/cyclin-dependent-kinases-4-and-6-inhibitors-cdk46i-versus-chemotherapy-luminal-b-early-breast 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/cyclin-dependent-kinases-4-and-6-inhibitors-cdk46i-versus-chemotherapy-luminal-b-early-breast 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/cyclin-dependent-kinases-4-and-6-inhibitors-cdk46i-versus-chemotherapy-luminal-b-early-breast 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/current-practice-approaching-controversial-diagnostic-and-therapeutic-topics-gastroenteropancreatic 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/current-practice-approaching-controversial-diagnostic-and-therapeutic-topics-gastroenteropancreatic 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/current-practice-approaching-controversial-diagnostic-and-therapeutic-topics-gastroenteropancreatic 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/immunotherapy-early-breast-cancer-too-soon-too-superficial-or-just-right 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/immunotherapy-early-breast-cancer-too-soon-too-superficial-or-just-right 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/immunotherapy-early-breast-cancer-too-soon-too-superficial-or-just-right 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/combined-quality-and-dose-volume-histograms-assessing-predictive-value-99mtc-maa-spectct-simulation 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/combined-quality-and-dose-volume-histograms-assessing-predictive-value-99mtc-maa-spectct-simulation 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/combined-quality-and-dose-volume-histograms-assessing-predictive-value-99mtc-maa-spectct-simulation 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/how-covid-19-pandemic-affected-cancer-progression-three-different-scenarios-evidenced-pet-imaging 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/how-covid-19-pandemic-affected-cancer-progression-three-different-scenarios-evidenced-pet-imaging 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/how-covid-19-pandemic-affected-cancer-progression-three-different-scenarios-evidenced-pet-imaging 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/hepatic-dysfunction-impairs-prognosis-critically-ill-patients-hematological-malignancies-post-hoc 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/hepatic-dysfunction-impairs-prognosis-critically-ill-patients-hematological-malignancies-post-hoc 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/hepatic-dysfunction-impairs-prognosis-critically-ill-patients-hematological-malignancies-post-hoc 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/inhibition-rank-signaling-breast-cancer-induces-anti-tumor-immune-response-orchestrated-cd8-t-cells 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/inhibition-rank-signaling-breast-cancer-induces-anti-tumor-immune-response-orchestrated-cd8-t-cells 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/inhibition-rank-signaling-breast-cancer-induces-anti-tumor-immune-response-orchestrated-cd8-t-cells 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/malignant-bowel-obstruction-effectiveness-and-safety-systemic-chemotherapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/malignant-bowel-obstruction-effectiveness-and-safety-systemic-chemotherapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/malignant-bowel-obstruction-effectiveness-and-safety-systemic-chemotherapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/recommendations-management-multiple-myeloma-2020 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/recommendations-management-multiple-myeloma-2020 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/recommendations-management-multiple-myeloma-2020 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/breast-reconstruction-perforator-flaps 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/breast-reconstruction-perforator-flaps 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/breast-reconstruction-perforator-flaps 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/association-between-histopathological-growth-patterns-liver-metastases-and-survival-after-hepatic 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/association-between-histopathological-growth-patterns-liver-metastases-and-survival-after-hepatic 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/association-between-histopathological-growth-patterns-liver-metastases-and-survival-after-hepatic 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/successful-treatment-synchronous-chemoresistant-pulmonary-metastasis-pleomorphic-rhabdomyosarcoma 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/successful-treatment-synchronous-chemoresistant-pulmonary-metastasis-pleomorphic-rhabdomyosarcoma 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/successful-treatment-synchronous-chemoresistant-pulmonary-metastasis-pleomorphic-rhabdomyosarcoma 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/organisation-time-and-caregivers 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/organisation-time-and-caregivers 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/organisation-time-and-caregivers 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/fat1-deletion-promotes-hybrid-emt-state-tumour-stemness-and-metastasis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/fat1-deletion-promotes-hybrid-emt-state-tumour-stemness-and-metastasis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/fat1-deletion-promotes-hybrid-emt-state-tumour-stemness-and-metastasis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/resume-de-these-dans-la-revue-medicale-de-bruxelles-une-belle-visibilite-au-sein-de-notre-faculte 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/resume-de-these-dans-la-revue-medicale-de-bruxelles-une-belle-visibilite-au-sein-de-notre-faculte 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/resume-de-these-dans-la-revue-medicale-de-bruxelles-une-belle-visibilite-au-sein-de-notre-faculte 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/les-54emes-journees-d-enseignement-postuniversitaire-de-l-amub 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/les-54emes-journees-d-enseignement-postuniversitaire-de-l-amub 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/les-54emes-journees-d-enseignement-postuniversitaire-de-l-amub 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/l-incertitude-dans-le-monde-et-le-monde-de-l-incertitude 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/l-incertitude-dans-le-monde-et-le-monde-de-l-incertitude 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/l-incertitude-dans-le-monde-et-le-monde-de-l-incertitude 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/l-amub-fait-peau-neuve 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/l-amub-fait-peau-neuve 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/l-amub-fait-peau-neuve 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/epidemies-et-sante-publique-du-besoin-d-une-communication-structuree-et-comprehensible 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/epidemies-et-sante-publique-du-besoin-d-une-communication-structuree-et-comprehensible 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/epidemies-et-sante-publique-du-besoin-d-une-communication-structuree-et-comprehensible 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/immunotherapie-et-tumeurs-oligometastatiques-rev-mal-respir-actualites 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/immunotherapie-et-tumeurs-oligometastatiques-rev-mal-respir-actualites 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/immunotherapie-et-tumeurs-oligometastatiques-rev-mal-respir-actualites 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/pandemie-virale-et-presse-scientifique-une-interaction-et-un-role-particuliers 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/pandemie-virale-et-presse-scientifique-une-interaction-et-un-role-particuliers 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/pandemie-virale-et-presse-scientifique-une-interaction-et-un-role-particuliers 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/lissa-le-pubmed-francophone 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/lissa-le-pubmed-francophone 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/lissa-le-pubmed-francophone 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/la-classification-tnm-en-pratique 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/la-classification-tnm-en-pratique 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/la-classification-tnm-en-pratique 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/update-management-metastatic-clear-cell-renal-cell-carcinoma-bsmo-expert-panel-recommendations 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/update-management-metastatic-clear-cell-renal-cell-carcinoma-bsmo-expert-panel-recommendations 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/update-management-metastatic-clear-cell-renal-cell-carcinoma-bsmo-expert-panel-recommendations 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/drug-related-problems-and-risk-factors-related-unplanned-hospital-readmission-among-cancer-patients 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/drug-related-problems-and-risk-factors-related-unplanned-hospital-readmission-among-cancer-patients 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/drug-related-problems-and-risk-factors-related-unplanned-hospital-readmission-among-cancer-patients 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/aging-bone-marrow-mesenchymal-stromal-cells-hematopoiesis-disturbances-and-potential-role 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/aging-bone-marrow-mesenchymal-stromal-cells-hematopoiesis-disturbances-and-potential-role 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/aging-bone-marrow-mesenchymal-stromal-cells-hematopoiesis-disturbances-and-potential-role 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/body-mass-index-and-weight-change-patients-her2-positive-early-breast-cancer-exploratory-analysis 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/body-mass-index-and-weight-change-patients-her2-positive-early-breast-cancer-exploratory-analysis 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/body-mass-index-and-weight-change-patients-her2-positive-early-breast-cancer-exploratory-analysis 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/multicenter-randomized-phase-2-peace-v-storm-trial-defining-best-salvage-treatment-oligorecurrent 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/multicenter-randomized-phase-2-peace-v-storm-trial-defining-best-salvage-treatment-oligorecurrent 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/multicenter-randomized-phase-2-peace-v-storm-trial-defining-best-salvage-treatment-oligorecurrent 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/covid-19-and-bcg-where-s-challenge 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/covid-19-and-bcg-where-s-challenge 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/covid-19-and-bcg-where-s-challenge 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/association-between-pertuzumab-associated-diarrhoea-and-rash-and-survival-outcomes-patients-her2 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/association-between-pertuzumab-associated-diarrhoea-and-rash-and-survival-outcomes-patients-her2 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/association-between-pertuzumab-associated-diarrhoea-and-rash-and-survival-outcomes-patients-her2 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/breast-conservation-and-axillary-management-after-primary-systemic-therapy-patients-early-stage 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/breast-conservation-and-axillary-management-after-primary-systemic-therapy-patients-early-stage 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/breast-conservation-and-axillary-management-after-primary-systemic-therapy-patients-early-stage 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/impact-hiv-infection-baseline-characteristics-and-survival-women-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/impact-hiv-infection-baseline-characteristics-and-survival-women-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/impact-hiv-infection-baseline-characteristics-and-survival-women-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/nutrition-education-medical-schools-nems-espen-position-paper 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/nutrition-education-medical-schools-nems-espen-position-paper-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/nutrition-education-medical-schools-nems-espen-position-paper 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/oncology-care-keep-it-going-learn-improve-act-white-paper-be-ipsen-all-be-000191-oct-2020 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/oncology-care-keep-it-going-learn-improve-act-white-paper-be-ipsen-all-be-000191-oct-2020 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/oncology-care-keep-it-going-learn-improve-act-white-paper-be-ipsen-all-be-000191-oct-2020 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/clinical-management-first-line-advanced-triple-negative-breast-cancer-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/clinical-management-first-line-advanced-triple-negative-breast-cancer-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/clinical-management-first-line-advanced-triple-negative-breast-cancer-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/necessite-d-un-plan-national-de-sante-pour-les-patients-oncologiques-pour-eviter-une-vague-de 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/necessite-d-un-plan-national-de-sante-pour-les-patients-oncologiques-pour-eviter-une-vague-de 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/necessite-d-un-plan-national-de-sante-pour-les-patients-oncologiques-pour-eviter-une-vague-de 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/immuno-comparative-screening-adult-derived-human-liver-stemprogenitor-cells-immune-inflammatory 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/immuno-comparative-screening-adult-derived-human-liver-stemprogenitor-cells-immune-inflammatory 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/immuno-comparative-screening-adult-derived-human-liver-stemprogenitor-cells-immune-inflammatory 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/perioperative-treatment-resected-non-small-cell-lung-cancer-which-option-2020 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/perioperative-treatment-resected-non-small-cell-lung-cancer-which-option-2020 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/perioperative-treatment-resected-non-small-cell-lung-cancer-which-option-2020 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/risk-factors-imminent-fractures-substudy-frisbee-cohort 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/risk-factors-imminent-fractures-substudy-frisbee-cohort 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/risk-factors-imminent-fractures-substudy-frisbee-cohort 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/initiation-new-anti-cancer-medical-treatment-icu-retrospective-study 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/initiation-new-anti-cancer-medical-treatment-icu-retrospective-study 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/initiation-new-anti-cancer-medical-treatment-icu-retrospective-study 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/biomarkers-early-diagnosis-hemophagocytic-lymphohistiocytosis-critically-ill-patients 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/biomarkers-early-diagnosis-hemophagocytic-lymphohistiocytosis-critically-ill-patients 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/biomarkers-early-diagnosis-hemophagocytic-lymphohistiocytosis-critically-ill-patients 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/liquid-biopsy-enters-clinic-implementation-issues-and-future-challenges 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/liquid-biopsy-enters-clinic-implementation-issues-and-future-challenges 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/liquid-biopsy-enters-clinic-implementation-issues-and-future-challenges 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/new-anti-leukemic-effect-carvacrol-and-thymol-combination-through-synergistic-induction-different 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/new-anti-leukemic-effect-carvacrol-and-thymol-combination-through-synergistic-induction-different 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/new-anti-leukemic-effect-carvacrol-and-thymol-combination-through-synergistic-induction-different 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/safety-and-immunogenicity-ly3415244-bispecific-antibody-against-tim-3-and-pd-l1-patients-advanced 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/safety-and-immunogenicity-ly3415244-bispecific-antibody-against-tim-3-and-pd-l1-patients-advanced 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/safety-and-immunogenicity-ly3415244-bispecific-antibody-against-tim-3-and-pd-l1-patients-advanced 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/rationale-and-design-regina-phase-ii-trial-neoadjuvant-regorafenib-nivolumab-and-short-course 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/rationale-and-design-regina-phase-ii-trial-neoadjuvant-regorafenib-nivolumab-and-short-course 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/rationale-and-design-regina-phase-ii-trial-neoadjuvant-regorafenib-nivolumab-and-short-course 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/oncological-outcomes-salvage-radical-prostatectomy-recurrent-prostate-cancer-contemporary-era 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/oncological-outcomes-salvage-radical-prostatectomy-recurrent-prostate-cancer-contemporary-era 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/oncological-outcomes-salvage-radical-prostatectomy-recurrent-prostate-cancer-contemporary-era 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/international-recommendations-personalised-selective-internal-radiation-therapy-primary-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/international-recommendations-personalised-selective-internal-radiation-therapy-primary-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/international-recommendations-personalised-selective-internal-radiation-therapy-primary-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/flexible-care-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/flexible-care-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/flexible-care-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/editorial-endocrine-tumors-rare-tumors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/editorial-endocrine-tumors-rare-tumors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/editorial-endocrine-tumors-rare-tumors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/peripheral-neurolytic-blocks 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/peripheral-neurolytic-blocks 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/peripheral-neurolytic-blocks 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/what-should-guide-performance-venous-resection-during-pancreaticoduodenectomy-pancreatic-ductal 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/what-should-guide-performance-venous-resection-during-pancreaticoduodenectomy-pancreatic-ductal 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/what-should-guide-performance-venous-resection-during-pancreaticoduodenectomy-pancreatic-ductal 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/hdr-brachytherapy-boost-using-mr-only-workflow-intermediate-and-high-risk-prostate-cancer-8-year 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/hdr-brachytherapy-boost-using-mr-only-workflow-intermediate-and-high-risk-prostate-cancer-8-year 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/hdr-brachytherapy-boost-using-mr-only-workflow-intermediate-and-high-risk-prostate-cancer-8-year 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/correction-combined-quality-and-dose-volume-histograms-assessing-predictive-value-99mtc-maa-spectct 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/correction-combined-quality-and-dose-volume-histograms-assessing-predictive-value-99mtc-maa-spectct 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/correction-combined-quality-and-dose-volume-histograms-assessing-predictive-value-99mtc-maa-spectct 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/performance-rox-index-predict-intubation-immunocompromised-patients-receiving-high-flow-nasal 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/performance-rox-index-predict-intubation-immunocompromised-patients-receiving-high-flow-nasal 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/performance-rox-index-predict-intubation-immunocompromised-patients-receiving-high-flow-nasal 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/diamorfosis-diagnosis-and-management-lung-cancer-and-fibrosis-survey-international-survey-and-call 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/diamorfosis-diagnosis-and-management-lung-cancer-and-fibrosis-survey-international-survey-and-call 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/diamorfosis-diagnosis-and-management-lung-cancer-and-fibrosis-survey-international-survey-and-call 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/health-related-quality-life-and-utility-outcomes-selinexor-relapsedrefractory-diffuse-large-b-cell 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/health-related-quality-life-and-utility-outcomes-selinexor-relapsedrefractory-diffuse-large-b-cell 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/health-related-quality-life-and-utility-outcomes-selinexor-relapsedrefractory-diffuse-large-b-cell 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/optimal-treatment-aromatase-inhibitor-resistant-metastatic-breast-cancer-patients-lessons-pearl 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/optimal-treatment-aromatase-inhibitor-resistant-metastatic-breast-cancer-patients-lessons-pearl 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/optimal-treatment-aromatase-inhibitor-resistant-metastatic-breast-cancer-patients-lessons-pearl 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/implementation-colonoscopy-quality-monitoring-belgian-university-hospital-integrated-computer-based 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/implementation-colonoscopy-quality-monitoring-belgian-university-hospital-integrated-computer-based 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/implementation-colonoscopy-quality-monitoring-belgian-university-hospital-integrated-computer-based 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/eus-guided-placement-fiducial-markers-stereotactic-body-radiation-therapy-pancreatic-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/eus-guided-placement-fiducial-markers-stereotactic-body-radiation-therapy-pancreatic-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/eus-guided-placement-fiducial-markers-stereotactic-body-radiation-therapy-pancreatic-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/investigation-relation-radiation-therapy-quality-toxicity-and-survival-lap07-phase-3-trial-locally 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/investigation-relation-radiation-therapy-quality-toxicity-and-survival-lap07-phase-3-trial-locally 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/investigation-relation-radiation-therapy-quality-toxicity-and-survival-lap07-phase-3-trial-locally 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/pan-cancer-analysis-whole-genomes 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/pan-cancer-analysis-whole-genomes 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/pan-cancer-analysis-whole-genomes 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/pneumocystis-infection-two-patients-treated-both-immune-checkpoint-inhibitor-and-corticoids 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/pneumocystis-infection-two-patients-treated-both-immune-checkpoint-inhibitor-and-corticoids 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/pneumocystis-infection-two-patients-treated-both-immune-checkpoint-inhibitor-and-corticoids 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/predictive-value-neutrophils-count-local-tumor-control-after-chemoradiotherapy-patients-locally 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/predictive-value-neutrophils-count-local-tumor-control-after-chemoradiotherapy-patients-locally 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/predictive-value-neutrophils-count-local-tumor-control-after-chemoradiotherapy-patients-locally 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/donor-derived-myeloid-heme-oxygenase-1-controls-development-graft-versus-host-disease 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/donor-derived-myeloid-heme-oxygenase-1-controls-development-graft-versus-host-disease 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/donor-derived-myeloid-heme-oxygenase-1-controls-development-graft-versus-host-disease 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/activation-interferon-signaling-pathway-associated-resistance-cdk46-inhibitors-and-immune 2021-02-15T07:00:04+01:00 0.5 https://bordet.makemeweb.dev/en/adjuvant-pertuzumab-and-trastuzumab-early-her2-positive-breast-cancer-aphinity-trial-6-years-follow 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/adjuvant-pertuzumab-and-trastuzumab-early-her2-positive-breast-cancer-aphinity-trial-6-years-follow 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/adjuvant-pertuzumab-and-trastuzumab-early-her2-positive-breast-cancer-aphinity-trial-6-years-follow 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/role-prophylactic-cranial-irradiation-small-cell-lung-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/role-prophylactic-cranial-irradiation-small-cell-lung-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/role-prophylactic-cranial-irradiation-small-cell-lung-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/safety-antitumor-activity-and-t-cell-responses-dose-ranging-phase-i-trial-oncolytic-peptide-ltx-315 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/safety-antitumor-activity-and-t-cell-responses-dose-ranging-phase-i-trial-oncolytic-peptide-ltx-315 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/safety-antitumor-activity-and-t-cell-responses-dose-ranging-phase-i-trial-oncolytic-peptide-ltx-315 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/hidradenitis-suppurativa-associated-childhood-and-lifetime-traumatic-events-case-control-study 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/hidradenitis-suppurativa-associated-childhood-and-lifetime-traumatic-events-case-control-study 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/hidradenitis-suppurativa-associated-childhood-and-lifetime-traumatic-events-case-control-study 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/neoadjuvant-immunotherapy-breast-cancer-paradigm-shift 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/neoadjuvant-immunotherapy-breast-cancer-paradigm-shift 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/neoadjuvant-immunotherapy-breast-cancer-paradigm-shift 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/pitfalls-assessing-stromal-tumor-infiltrating-lymphocytes-stils-breast-cancer-0 2021-02-22T07:00:18+01:00 0.5 https://bordet.makemeweb.dev/en/clinical-behavior-and-outcomes-breast-cancer-young-women-germline-brca-pathogenic-variants 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/clinical-behavior-and-outcomes-breast-cancer-young-women-germline-brca-pathogenic-variants 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/clinical-behavior-and-outcomes-breast-cancer-young-women-germline-brca-pathogenic-variants 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/report-computational-assessment-tumor-infiltrating-lymphocytes-international-immuno-oncology-0 2021-02-22T07:00:18+01:00 0.5 https://bordet.makemeweb.dev/en/retrospective-evaluation-whole-exome-and-genome-mutation-calls-746-cancer-samples 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/retrospective-evaluation-whole-exome-and-genome-mutation-calls-746-cancer-samples 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/retrospective-evaluation-whole-exome-and-genome-mutation-calls-746-cancer-samples 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/sex-differences-oncogenic-mutational-processes 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/sex-differences-oncogenic-mutational-processes 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/sex-differences-oncogenic-mutational-processes 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/absence-benefit-perioperative-chemotherapy-initially-resectable-peritoneal-metastases-colorectal 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/absence-benefit-perioperative-chemotherapy-initially-resectable-peritoneal-metastases-colorectal 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/absence-benefit-perioperative-chemotherapy-initially-resectable-peritoneal-metastases-colorectal 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/prognostic-role-neutrophil-lymphocyte-ratio-nlr-urological-tumors-umbrella-review-evidence 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/prognostic-role-neutrophil-lymphocyte-ratio-nlr-urological-tumors-umbrella-review-evidence 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/prognostic-role-neutrophil-lymphocyte-ratio-nlr-urological-tumors-umbrella-review-evidence 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/rna-based-approaches-profile-oncogenic-pathways-low-quantity-samples-drive-precision-oncology 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/rna-based-approaches-profile-oncogenic-pathways-low-quantity-samples-drive-precision-oncology 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/rna-based-approaches-profile-oncogenic-pathways-low-quantity-samples-drive-precision-oncology 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/line-field-confocal-optical-coherence-tomography-basal-cell-carcinoma-descriptive-study 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/line-field-confocal-optical-coherence-tomography-basal-cell-carcinoma-descriptive-study 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/line-field-confocal-optical-coherence-tomography-basal-cell-carcinoma-descriptive-study 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/cross-species-analysis-enhancer-logic-using-deep-learning 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/cross-species-analysis-enhancer-logic-using-deep-learning 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/cross-species-analysis-enhancer-logic-using-deep-learning 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/cdk46-inhibitors-adjuvant-treatment-hormone-receptor-positive-her2-negative-early-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/cdk46-inhibitors-adjuvant-treatment-hormone-receptor-positive-her2-negative-early-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/cdk46-inhibitors-adjuvant-treatment-hormone-receptor-positive-her2-negative-early-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/70-gene-signature-aid-treatment-decisions-early-breast-cancer-updated-results-phase-3-randomised 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/70-gene-signature-aid-treatment-decisions-early-breast-cancer-updated-results-phase-3-randomised 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/70-gene-signature-aid-treatment-decisions-early-breast-cancer-updated-results-phase-3-randomised 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/cardiotoxicity-immune-checkpoint-inhibitors-systematic-review-and-meta-analysis-randomised-clinical 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/cardiotoxicity-immune-checkpoint-inhibitors-systematic-review-and-meta-analysis-randomised-clinical 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/cardiotoxicity-immune-checkpoint-inhibitors-systematic-review-and-meta-analysis-randomised-clinical 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/cdk46-and-pi3k-inhibitors-new-promise-patients-her2-positive-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/cdk46-and-pi3k-inhibitors-new-promise-patients-her2-positive-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/cdk46-and-pi3k-inhibitors-new-promise-patients-her2-positive-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/complete-pathological-response-neoadjuvant-treatment-associated-better-survival-outcomes-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/complete-pathological-response-neoadjuvant-treatment-associated-better-survival-outcomes-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/complete-pathological-response-neoadjuvant-treatment-associated-better-survival-outcomes-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/beta-blockers-early-stage-breast-cancer-systematic-review-and-meta-analysis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/beta-blockers-early-stage-breast-cancer-systematic-review-and-meta-analysis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/beta-blockers-early-stage-breast-cancer-systematic-review-and-meta-analysis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/analysing-attributes-comprehensive-cancer-centres-and-cancer-centres-across-europe-identify-key 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/analysing-attributes-comprehensive-cancer-centres-and-cancer-centres-across-europe-identify-key 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/analysing-attributes-comprehensive-cancer-centres-and-cancer-centres-across-europe-identify-key 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/dasatinib-stimulates-its-own-mechanism-resistance-activating-crtc3mitfbcl-2-pathway-melanoma-mutant 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/dasatinib-stimulates-its-own-mechanism-resistance-activating-crtc3mitfbcl-2-pathway-melanoma-mutant 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/dasatinib-stimulates-its-own-mechanism-resistance-activating-crtc3mitfbcl-2-pathway-melanoma-mutant 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/report-dose-medium-clinical-trials-where-available-consensus-global-harmonisation-group-maximize 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/report-dose-medium-clinical-trials-where-available-consensus-global-harmonisation-group-maximize 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/report-dose-medium-clinical-trials-where-available-consensus-global-harmonisation-group-maximize 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/linac-based-stereotactic-ablative-radiotherapy-pancreatic-cancer-intrafractional-triggered-imaging 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/linac-based-stereotactic-ablative-radiotherapy-pancreatic-cancer-intrafractional-triggered-imaging 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/linac-based-stereotactic-ablative-radiotherapy-pancreatic-cancer-intrafractional-triggered-imaging 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/balloon-occluded-chemoembolization-hepatocellular-carcinoma-prospective-study-safety-feasibility 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/balloon-occluded-chemoembolization-hepatocellular-carcinoma-prospective-study-safety-feasibility 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/balloon-occluded-chemoembolization-hepatocellular-carcinoma-prospective-study-safety-feasibility 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/comparing-cost-non-metastatic-breast-cancer-care-low-income-vs-high-income-country-plea-optimal 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/comparing-cost-non-metastatic-breast-cancer-care-low-income-vs-high-income-country-plea-optimal 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/comparing-cost-non-metastatic-breast-cancer-care-low-income-vs-high-income-country-plea-optimal 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/undifferentiated-pancreatic-carcinoma-osteoclast-giant-cells-what-do-we-know-so-far 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/undifferentiated-pancreatic-carcinoma-osteoclast-giant-cells-what-do-we-know-so-far 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/undifferentiated-pancreatic-carcinoma-osteoclast-giant-cells-what-do-we-know-so-far 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/supportive-care-cancer-patients-survey-available-settings-and-current-practices-belgium 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/supportive-care-cancer-patients-survey-available-settings-and-current-practices-belgium 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/supportive-care-cancer-patients-survey-available-settings-and-current-practices-belgium 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/correction-risk-relapse-after-anti-pd1-discontinuation-patients-hodgkin-lymphoma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/correction-risk-relapse-after-anti-pd1-discontinuation-patients-hodgkin-lymphoma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/correction-risk-relapse-after-anti-pd1-discontinuation-patients-hodgkin-lymphoma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/editorial-quality-assessment-across-disciplines-head-and-neck-cancer-treatment 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/editorial-quality-assessment-across-disciplines-head-and-neck-cancer-treatment 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/editorial-quality-assessment-across-disciplines-head-and-neck-cancer-treatment 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/clinico-metabolic-characterization-improves-prognostic-value-histological-growth-patterns-patients 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/clinico-metabolic-characterization-improves-prognostic-value-histological-growth-patterns-patients 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/clinico-metabolic-characterization-improves-prognostic-value-histological-growth-patterns-patients 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/allogeneic-transplantation-after-pd-1-blockade-classic-hodgkin-lymphoma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/allogeneic-transplantation-after-pd-1-blockade-classic-hodgkin-lymphoma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/allogeneic-transplantation-after-pd-1-blockade-classic-hodgkin-lymphoma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/papillary-immature-squamous-metaplasia-anal-canal-rare-probably-underdiagnosed-entity 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/papillary-immature-squamous-metaplasia-anal-canal-rare-probably-underdiagnosed-entity 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/papillary-immature-squamous-metaplasia-anal-canal-rare-probably-underdiagnosed-entity 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/mantle-cell-lymphoma-simulating-inflammatory-bowel-disease 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/mantle-cell-lymphoma-simulating-inflammatory-bowel-disease 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/mantle-cell-lymphoma-simulating-inflammatory-bowel-disease 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/identifying-frailty-clinically-fit-patients-diagnosed-hematological-malignancies-using-simple 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/identifying-frailty-clinically-fit-patients-diagnosed-hematological-malignancies-using-simple 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/identifying-frailty-clinically-fit-patients-diagnosed-hematological-malignancies-using-simple 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/rare-features-dermatomyositis-patient-ovarian-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/rare-features-dermatomyositis-patient-ovarian-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/rare-features-dermatomyositis-patient-ovarian-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/leukemia-inhibitory-factor-potential-biomarker-and-therapeutic-target-pancreatic-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/leukemia-inhibitory-factor-potential-biomarker-and-therapeutic-target-pancreatic-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/leukemia-inhibitory-factor-potential-biomarker-and-therapeutic-target-pancreatic-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/line-field-confocal-optical-coherence-tomography-benign-dermal-melanocytic-proliferations-case 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/line-field-confocal-optical-coherence-tomography-benign-dermal-melanocytic-proliferations-case 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/line-field-confocal-optical-coherence-tomography-benign-dermal-melanocytic-proliferations-case 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/line-field-confocal-optical-coherence-tomography-adjunctive-tool-diagnosis-autoimmune-bullous 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/line-field-confocal-optical-coherence-tomography-adjunctive-tool-diagnosis-autoimmune-bullous 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/line-field-confocal-optical-coherence-tomography-adjunctive-tool-diagnosis-autoimmune-bullous 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/severity-anosmia-early-symptom-covid-19-infection-may-predict-lasting-loss-smell 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/severity-anosmia-early-symptom-covid-19-infection-may-predict-lasting-loss-smell 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/severity-anosmia-early-symptom-covid-19-infection-may-predict-lasting-loss-smell 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/frontline-treatment-combination-obinutuzumab-chlorambucil-chronic-lymphocytic-leukemia-outside 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/frontline-treatment-combination-obinutuzumab-chlorambucil-chronic-lymphocytic-leukemia-outside 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/frontline-treatment-combination-obinutuzumab-chlorambucil-chronic-lymphocytic-leukemia-outside 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/pcip-seq-simultaneous-sequencing-integrated-viral-genomes-and-their-insertion-sites-long-reads 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/pcip-seq-simultaneous-sequencing-integrated-viral-genomes-and-their-insertion-sites-long-reads 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/pcip-seq-simultaneous-sequencing-integrated-viral-genomes-and-their-insertion-sites-long-reads 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/biases-study-design-implementation-and-data-analysis-distort-appraisal-clinical-benefit-and-esmo 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/biases-study-design-implementation-and-data-analysis-distort-appraisal-clinical-benefit-and-esmo 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/biases-study-design-implementation-and-data-analysis-distort-appraisal-clinical-benefit-and-esmo 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/anal-squamous-cell-carcinoma-standards-care-new-data-and-ongoing-clinical-trials 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/anal-squamous-cell-carcinoma-standards-care-new-data-and-ongoing-clinical-trials 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/anal-squamous-cell-carcinoma-standards-care-new-data-and-ongoing-clinical-trials 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/factors-associated-sars-cov-2-infection-and-outcome-patients-solid-tumors-or-hematological 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/factors-associated-sars-cov-2-infection-and-outcome-patients-solid-tumors-or-hematological 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/factors-associated-sars-cov-2-infection-and-outcome-patients-solid-tumors-or-hematological 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/sacituzumab-govitecan-metastatic-triple-negative-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/sacituzumab-govitecan-metastatic-triple-negative-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/sacituzumab-govitecan-metastatic-triple-negative-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/investigating-intrinsic-radiosensitivity-biomarkers-peptide-receptor-radionuclide-therapy-177lulu 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/investigating-intrinsic-radiosensitivity-biomarkers-peptide-receptor-radionuclide-therapy-177lulu 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/investigating-intrinsic-radiosensitivity-biomarkers-peptide-receptor-radionuclide-therapy-177lulu 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/split-vmat-technique-control-deep-inspiration-breath-hold-time-breast-cancer-radiotherapy 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/split-vmat-technique-control-deep-inspiration-breath-hold-time-breast-cancer-radiotherapy 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/split-vmat-technique-control-deep-inspiration-breath-hold-time-breast-cancer-radiotherapy 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/reporting-and-analysis-framework-structured-evaluation-covid-19-clinical-and-imaging-data 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/reporting-and-analysis-framework-structured-evaluation-covid-19-clinical-and-imaging-data 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/reporting-and-analysis-framework-structured-evaluation-covid-19-clinical-and-imaging-data 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/author-correction-retrospective-evaluation-whole-exome-and-genome-mutation-calls-746-cancer-samples 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/author-correction-retrospective-evaluation-whole-exome-and-genome-mutation-calls-746-cancer-samples 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/author-correction-retrospective-evaluation-whole-exome-and-genome-mutation-calls-746-cancer-samples 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/tumor-cellularity-and-infiltrating-lymphocytes-celtil-survival-surrogate-her2-positive-breast 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/tumor-cellularity-and-infiltrating-lymphocytes-celtil-survival-surrogate-her2-positive-breast 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/tumor-cellularity-and-infiltrating-lymphocytes-celtil-survival-surrogate-her2-positive-breast 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/priming-mesenchymal-stem-cells-hydrosoluble-form-curcumin-allows-keeping-their-mesenchymal 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/priming-mesenchymal-stem-cells-hydrosoluble-form-curcumin-allows-keeping-their-mesenchymal 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/priming-mesenchymal-stem-cells-hydrosoluble-form-curcumin-allows-keeping-their-mesenchymal 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/impact-covid-19-social-media-perceived-oncology-community-results-survey-collaboration-european 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/impact-covid-19-social-media-perceived-oncology-community-results-survey-collaboration-european 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/impact-covid-19-social-media-perceived-oncology-community-results-survey-collaboration-european 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/oncoalert-round-table-discussions-global-covid-19-experience 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/oncoalert-round-table-discussions-global-covid-19-experience 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/oncoalert-round-table-discussions-global-covid-19-experience 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/emerging-therapeutics-patients-triple-negative-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/emerging-therapeutics-patients-triple-negative-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/emerging-therapeutics-patients-triple-negative-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/patient-reported-function-health-related-quality-life-and-symptoms-aphinity-pertuzumab-plus 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/patient-reported-function-health-related-quality-life-and-symptoms-aphinity-pertuzumab-plus 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/patient-reported-function-health-related-quality-life-and-symptoms-aphinity-pertuzumab-plus 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/line-field-confocal-optical-coherence-tomography-sebaceous-hyperplasia-case-series 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/line-field-confocal-optical-coherence-tomography-sebaceous-hyperplasia-case-series 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/line-field-confocal-optical-coherence-tomography-sebaceous-hyperplasia-case-series 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/monte-carlo-quality-control-tool-stereotactic-body-radiation-therapy-treatment-plans 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/monte-carlo-quality-control-tool-stereotactic-body-radiation-therapy-treatment-plans 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/monte-carlo-quality-control-tool-stereotactic-body-radiation-therapy-treatment-plans 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/updated-results-international-phase-iii-altto-trial-big-2-06alliance-n063d 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/updated-results-international-phase-iii-altto-trial-big-2-06alliance-n063d 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/updated-results-international-phase-iii-altto-trial-big-2-06alliance-n063d 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/impact-covid-19-pandemic-patients-and-staff-radiation-oncology-departments-belgium-national-survey 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/impact-covid-19-pandemic-patients-and-staff-radiation-oncology-departments-belgium-national-survey 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/impact-covid-19-pandemic-patients-and-staff-radiation-oncology-departments-belgium-national-survey 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/sarcoidosis-versus-lymphoma 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/sarcoidosis-versus-lymphoma 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/sarcoidosis-versus-lymphoma 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/pancreatic-ductal-adenocarcinoma-arising-young-and-old-patients-displays-similar-molecular-features 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/pancreatic-ductal-adenocarcinoma-arising-young-and-old-patients-displays-similar-molecular-features 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/pancreatic-ductal-adenocarcinoma-arising-young-and-old-patients-displays-similar-molecular-features 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/pancreatic-cancer-meets-human-microbiota-close-encounters-third-kind 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/pancreatic-cancer-meets-human-microbiota-close-encounters-third-kind 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/pancreatic-cancer-meets-human-microbiota-close-encounters-third-kind 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/stem-cell-transplantation-diamond-blackfan-anemia-retrospective-study-behalf-severe-aplastic-anemia 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/stem-cell-transplantation-diamond-blackfan-anemia-retrospective-study-behalf-severe-aplastic-anemia 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/stem-cell-transplantation-diamond-blackfan-anemia-retrospective-study-behalf-severe-aplastic-anemia 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/improving-generalization-mr-ct-synthesis-radiotherapy-using-augmented-cycle-generative-adversarial 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/improving-generalization-mr-ct-synthesis-radiotherapy-using-augmented-cycle-generative-adversarial 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/improving-generalization-mr-ct-synthesis-radiotherapy-using-augmented-cycle-generative-adversarial 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/high-dimensional-analysis-adenosine-pathway-high-grade-serous-ovarian-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/high-dimensional-analysis-adenosine-pathway-high-grade-serous-ovarian-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/high-dimensional-analysis-adenosine-pathway-high-grade-serous-ovarian-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/sapanisertib-plus-exemestane-or-fulvestrant-women-hormone-receptor-positiveher2-negative-advanced 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/sapanisertib-plus-exemestane-or-fulvestrant-women-hormone-receptor-positiveher2-negative-advanced 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/sapanisertib-plus-exemestane-or-fulvestrant-women-hormone-receptor-positiveher2-negative-advanced 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/exciting-new-field-her2-low-breast-cancer-treatment 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/exciting-new-field-her2-low-breast-cancer-treatment 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/exciting-new-field-her2-low-breast-cancer-treatment 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/clinical-outcomes-platinum-based-chemotherapy-patients-advanced-breast-cancer-11-year-single 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/clinical-outcomes-platinum-based-chemotherapy-patients-advanced-breast-cancer-11-year-single 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/clinical-outcomes-platinum-based-chemotherapy-patients-advanced-breast-cancer-11-year-single 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/near-infrared-fluorescence-imaging-breast-cancer-and-axillary-lymph-nodes-after-intravenous 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/near-infrared-fluorescence-imaging-breast-cancer-and-axillary-lymph-nodes-after-intravenous 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/near-infrared-fluorescence-imaging-breast-cancer-and-axillary-lymph-nodes-after-intravenous 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/immune-checkpoint-inhibitors-bcg-resistant-nmibc-dawn-new-era 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/immune-checkpoint-inhibitors-bcg-resistant-nmibc-dawn-new-era 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/immune-checkpoint-inhibitors-bcg-resistant-nmibc-dawn-new-era 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/total-neoadjuvant-therapy-rectal-cancer-making-sense-results-rapido-and-prodige-23-trials 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/total-neoadjuvant-therapy-rectal-cancer-making-sense-results-rapido-and-prodige-23-trials 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/total-neoadjuvant-therapy-rectal-cancer-making-sense-results-rapido-and-prodige-23-trials 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/overcoming-barriers-clinical-trials-cooperation-breast-international-group-example 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/overcoming-barriers-clinical-trials-cooperation-breast-international-group-example 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/overcoming-barriers-clinical-trials-cooperation-breast-international-group-example 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/interpretation-allele-specific-chromatin-accessibility-using-cell-state-aware-deep-learning 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/interpretation-allele-specific-chromatin-accessibility-using-cell-state-aware-deep-learning 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/interpretation-allele-specific-chromatin-accessibility-using-cell-state-aware-deep-learning 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/edemas-face-and-lymphoscintigraphic-examination 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/edemas-face-and-lymphoscintigraphic-examination 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/edemas-face-and-lymphoscintigraphic-examination 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/systemic-pro-inflammatory-response-identifies-patients-cancer-adverse-outcomes-sars-cov-2-infection 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/systemic-pro-inflammatory-response-identifies-patients-cancer-adverse-outcomes-sars-cov-2-infection 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/systemic-pro-inflammatory-response-identifies-patients-cancer-adverse-outcomes-sars-cov-2-infection 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/endoscopic-bariatric-and-metabolic-therapies-nonalcoholic-fatty-liver-disease-enough-data-be 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/endoscopic-bariatric-and-metabolic-therapies-nonalcoholic-fatty-liver-disease-enough-data-be 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/endoscopic-bariatric-and-metabolic-therapies-nonalcoholic-fatty-liver-disease-enough-data-be 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/evidence-based-approaches-management-side-effects-adjuvant-endocrine-therapy-patients-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/evidence-based-approaches-management-side-effects-adjuvant-endocrine-therapy-patients-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/evidence-based-approaches-management-side-effects-adjuvant-endocrine-therapy-patients-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/risk-factors-breast-cancer-overall-and-tumor-subtype-among-women-mozambique-sub-saharan-africa 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/risk-factors-breast-cancer-overall-and-tumor-subtype-among-women-mozambique-sub-saharan-africa 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/risk-factors-breast-cancer-overall-and-tumor-subtype-among-women-mozambique-sub-saharan-africa 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/performance-xpert-mtbrif-ultra-diagnosis-pulmonary-and-extra-pulmonary-tuberculosis-one-year-use 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/performance-xpert-mtbrif-ultra-diagnosis-pulmonary-and-extra-pulmonary-tuberculosis-one-year-use 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/performance-xpert-mtbrif-ultra-diagnosis-pulmonary-and-extra-pulmonary-tuberculosis-one-year-use 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/effectiveness-and-toxicity-adjuvant-chemotherapy-patients-non-small-cell-lung-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/effectiveness-and-toxicity-adjuvant-chemotherapy-patients-non-small-cell-lung-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/effectiveness-and-toxicity-adjuvant-chemotherapy-patients-non-small-cell-lung-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/inhibiting-mnk12-eif4e-axis-impairs-melanoma-phenotype-switching-and-potentiates-anti-tumor-immune 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/inhibiting-mnk12-eif4e-axis-impairs-melanoma-phenotype-switching-and-potentiates-anti-tumor-immune 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/inhibiting-mnk12-eif4e-axis-impairs-melanoma-phenotype-switching-and-potentiates-anti-tumor-immune 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/correction-phase-ii-study-abemaciclib-patients-brain-metastases-secondary-hormone-receptor-positive 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/correction-phase-ii-study-abemaciclib-patients-brain-metastases-secondary-hormone-receptor-positive 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/correction-phase-ii-study-abemaciclib-patients-brain-metastases-secondary-hormone-receptor-positive 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/mesenchymal-stemstromal-cell-therapeutic-features-bridge-between-bench-and-clinic 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/mesenchymal-stemstromal-cell-therapeutic-features-bridge-between-bench-and-clinic 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/mesenchymal-stemstromal-cell-therapeutic-features-bridge-between-bench-and-clinic 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/role-p53-expression-patients-rasbraf-wild-type-metastatic-colorectal-cancer-receiving-irinotecan 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/role-p53-expression-patients-rasbraf-wild-type-metastatic-colorectal-cancer-receiving-irinotecan 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/role-p53-expression-patients-rasbraf-wild-type-metastatic-colorectal-cancer-receiving-irinotecan 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/salvage-stereotactic-body-radiotherapy-sbrt-intraprostatic-relapse-after-prostate-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/salvage-stereotactic-body-radiotherapy-sbrt-intraprostatic-relapse-after-prostate-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/salvage-stereotactic-body-radiotherapy-sbrt-intraprostatic-relapse-after-prostate-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/state-art-and-future-directions-systemic-treatment-neuroendocrine-neoplasms 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/state-art-and-future-directions-systemic-treatment-neuroendocrine-neoplasms 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/state-art-and-future-directions-systemic-treatment-neuroendocrine-neoplasms 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/pudendal-nerve-entrapment-potential-cause-weak-ejaculation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/pudendal-nerve-entrapment-potential-cause-weak-ejaculation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/pudendal-nerve-entrapment-potential-cause-weak-ejaculation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/definition-and-standardization-histocompatibility-requests-depending-patient-course-and-donor-type 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/definition-and-standardization-histocompatibility-requests-depending-patient-course-and-donor-type 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/definition-and-standardization-histocompatibility-requests-depending-patient-course-and-donor-type 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/luminal-breast-cancer-risk-recurrence-and-tumor-associated-immune-suppression 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/luminal-breast-cancer-risk-recurrence-and-tumor-associated-immune-suppression 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/luminal-breast-cancer-risk-recurrence-and-tumor-associated-immune-suppression 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/editorial-radioembolization-metastatic-colorectal-cancer-towards-maturity-last 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/editorial-radioembolization-metastatic-colorectal-cancer-towards-maturity-last 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/editorial-radioembolization-metastatic-colorectal-cancer-towards-maturity-last 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/checkpoint-inhibition-combination-immunoboost-external-beam-radiotherapy-solid-tumors-cheers-study 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/checkpoint-inhibition-combination-immunoboost-external-beam-radiotherapy-solid-tumors-cheers-study 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/checkpoint-inhibition-combination-immunoboost-external-beam-radiotherapy-solid-tumors-cheers-study 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/immune-mediated-drug-induced-liver-injury-immunogenetics-and-experimental-models 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/immune-mediated-drug-induced-liver-injury-immunogenetics-and-experimental-models 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/immune-mediated-drug-induced-liver-injury-immunogenetics-and-experimental-models 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/malignant-phyllodes-tumor-breast-practice-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/malignant-phyllodes-tumor-breast-practice-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/malignant-phyllodes-tumor-breast-practice-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/murlentamab-low-fucosylated-anti-mullerian-hormone-type-ii-receptor-amhrii-antibody-exhibits-anti 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/murlentamab-low-fucosylated-anti-mullerian-hormone-type-ii-receptor-amhrii-antibody-exhibits-anti 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/murlentamab-low-fucosylated-anti-mullerian-hormone-type-ii-receptor-amhrii-antibody-exhibits-anti 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/determinants-enhanced-vulnerability-coronavirus-disease-2019-uk-patients-cancer-european-study 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/determinants-enhanced-vulnerability-coronavirus-disease-2019-uk-patients-cancer-european-study 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/determinants-enhanced-vulnerability-coronavirus-disease-2019-uk-patients-cancer-european-study 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/phase-i-study-ido-1-inhibitor-ly3381916-monotherapy-and-combination-anti-pd-l1-antibody-ly3300054 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/phase-i-study-ido-1-inhibitor-ly3381916-monotherapy-and-combination-anti-pd-l1-antibody-ly3300054 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/phase-i-study-ido-1-inhibitor-ly3381916-monotherapy-and-combination-anti-pd-l1-antibody-ly3300054 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/nutrition-education-medical-schools-nems-project-joining-espen-and-university-point-view 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/nutrition-education-medical-schools-nems-project-joining-espen-and-university-point-view 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/nutrition-education-medical-schools-nems-project-joining-espen-and-university-point-view 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/assessment-cough-head-and-neck-cancer-patients-risk-dysphagia-overview 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/assessment-cough-head-and-neck-cancer-patients-risk-dysphagia-overview 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/assessment-cough-head-and-neck-cancer-patients-risk-dysphagia-overview 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/rtk-inhibitors-melanoma-bench-bedside 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/rtk-inhibitors-melanoma-bench-bedside 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/rtk-inhibitors-melanoma-bench-bedside 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/clinical-outcomes-patients-philadelphia-chromosome-positive-leukemia-treated-ponatinib-routine 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/clinical-outcomes-patients-philadelphia-chromosome-positive-leukemia-treated-ponatinib-routine 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/clinical-outcomes-patients-philadelphia-chromosome-positive-leukemia-treated-ponatinib-routine 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/genomic-landscape-carcinomas-mucinous-differentiation 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/genomic-landscape-carcinomas-mucinous-differentiation 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/genomic-landscape-carcinomas-mucinous-differentiation 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/evaluation-xvi-dual-registration-tool-image-guided-radiotherapy-prostate-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/evaluation-xvi-dual-registration-tool-image-guided-radiotherapy-prostate-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/evaluation-xvi-dual-registration-tool-image-guided-radiotherapy-prostate-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/lung-cancer-screening-low-dose-computed-tomography-systematic-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/lung-cancer-screening-low-dose-computed-tomography-systematic-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/lung-cancer-screening-low-dose-computed-tomography-systematic-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/prostate-cancer-and-reactive-haemophagocytic-lymphohistiocytosis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/prostate-cancer-and-reactive-haemophagocytic-lymphohistiocytosis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/prostate-cancer-and-reactive-haemophagocytic-lymphohistiocytosis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/antibody-drug-conjugates-immune-checkpoint-inhibitors-and-their-combination-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/antibody-drug-conjugates-immune-checkpoint-inhibitors-and-their-combination-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/antibody-drug-conjugates-immune-checkpoint-inhibitors-and-their-combination-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/chemotherapy-de-escalation-using-18f-fdg-pet-based-pathological-response-adapted-strategy-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/chemotherapy-de-escalation-using-18f-fdg-pet-based-pathological-response-adapted-strategy-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/chemotherapy-de-escalation-using-18f-fdg-pet-based-pathological-response-adapted-strategy-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/hyponatremia-cancer-patients-hospitalized-palliative-care-department-cross-sectional-analysis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/hyponatremia-cancer-patients-hospitalized-palliative-care-department-cross-sectional-analysis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/hyponatremia-cancer-patients-hospitalized-palliative-care-department-cross-sectional-analysis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/artificial-intelligence-magnetic-resonance-guided-radiotherapy-medical-and-physical-considerations 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/artificial-intelligence-magnetic-resonance-guided-radiotherapy-medical-and-physical-considerations 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/artificial-intelligence-magnetic-resonance-guided-radiotherapy-medical-and-physical-considerations 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/preoperative-and-postoperative-radiotherapy-rt-non-small-cell-lung-cancer-still-open-question 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/preoperative-and-postoperative-radiotherapy-rt-non-small-cell-lung-cancer-still-open-question 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/preoperative-and-postoperative-radiotherapy-rt-non-small-cell-lung-cancer-still-open-question 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/new-treatment-strategy-targeting-galectin-1-against-thyroid-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/new-treatment-strategy-targeting-galectin-1-against-thyroid-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/new-treatment-strategy-targeting-galectin-1-against-thyroid-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/bsw-light-first-completely-virtual-surgical-congress-belgium-out-box 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/bsw-light-first-completely-virtual-surgical-congress-belgium-out-box 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/bsw-light-first-completely-virtual-surgical-congress-belgium-out-box 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/impact-first-wave-sars-cov-2covid-19-pandemic-digestive-surgical-activities-belgian-national-survey 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/impact-first-wave-sars-cov-2covid-19-pandemic-digestive-surgical-activities-belgian-national-survey 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/impact-first-wave-sars-cov-2covid-19-pandemic-digestive-surgical-activities-belgian-national-survey 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/effect-oxidized-low-density-lipoprotein-head-and-neck-squamous-cell-carcinomas 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/effect-oxidized-low-density-lipoprotein-head-and-neck-squamous-cell-carcinomas 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/effect-oxidized-low-density-lipoprotein-head-and-neck-squamous-cell-carcinomas 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/fortnightly-or-fractionated-weekly-docetaxel-cisplatin-5-fu-first-line-treatment-advanced-gastric 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/fortnightly-or-fractionated-weekly-docetaxel-cisplatin-5-fu-first-line-treatment-advanced-gastric 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/fortnightly-or-fractionated-weekly-docetaxel-cisplatin-5-fu-first-line-treatment-advanced-gastric 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/mortality-adult-patients-solid-or-hematological-malignancies-and-sars-cov-2-infection-specific 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/mortality-adult-patients-solid-or-hematological-malignancies-and-sars-cov-2-infection-specific 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/mortality-adult-patients-solid-or-hematological-malignancies-and-sars-cov-2-infection-specific 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/precision-medicine-breast-cancer-clinical-trials-clinical-practice 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/precision-medicine-breast-cancer-clinical-trials-clinical-practice 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/precision-medicine-breast-cancer-clinical-trials-clinical-practice 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/management-thymoma-associated-autoimmune-pure-red-cell-aplasia-case-report-and-systematic-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/management-thymoma-associated-autoimmune-pure-red-cell-aplasia-case-report-and-systematic-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/management-thymoma-associated-autoimmune-pure-red-cell-aplasia-case-report-and-systematic-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/heparanase-potential-marker-worse-prognosis-estrogen-receptor-positive-breast-cancer 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/heparanase-potential-marker-worse-prognosis-estrogen-receptor-positive-breast-cancer 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/heparanase-potential-marker-worse-prognosis-estrogen-receptor-positive-breast-cancer 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/thoracic-paravertebral-block 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/thoracic-paravertebral-block 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/thoracic-paravertebral-block 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/hyperthermic-intraperitoneal-chemotherapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/hyperthermic-intraperitoneal-chemotherapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/hyperthermic-intraperitoneal-chemotherapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/pericapsular-nerve-group-block 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/pericapsular-nerve-group-block 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/pericapsular-nerve-group-block 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/regional-anesthesia-breast-reconstruction 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/regional-anesthesia-breast-reconstruction 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/regional-anesthesia-breast-reconstruction 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/hookworm-treatment-induces-decrease-suppressive-regulatory-t-cell-associated-th2-inflammatory 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/hookworm-treatment-induces-decrease-suppressive-regulatory-t-cell-associated-th2-inflammatory 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/hookworm-treatment-induces-decrease-suppressive-regulatory-t-cell-associated-th2-inflammatory 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/editorial-supportive-care-cancer-patients-quo-vadis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/editorial-supportive-care-cancer-patients-quo-vadis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/editorial-supportive-care-cancer-patients-quo-vadis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/prevalence-and-clinical-impact-tumor-brca1-and-brca2-mutations-patients-presenting-localized-or 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/prevalence-and-clinical-impact-tumor-brca1-and-brca2-mutations-patients-presenting-localized-or 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/prevalence-and-clinical-impact-tumor-brca1-and-brca2-mutations-patients-presenting-localized-or 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/treatments-outcomes-histological-variants-and-non-urothelial-bladder-cancer-results-multicenter 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/treatments-outcomes-histological-variants-and-non-urothelial-bladder-cancer-results-multicenter 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/treatments-outcomes-histological-variants-and-non-urothelial-bladder-cancer-results-multicenter 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/gene-expression-signatures-tailoring-adjuvant-chemotherapy-luminal-breast-cancer-stronger-evidence 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/gene-expression-signatures-tailoring-adjuvant-chemotherapy-luminal-breast-cancer-stronger-evidence 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/gene-expression-signatures-tailoring-adjuvant-chemotherapy-luminal-breast-cancer-stronger-evidence 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/prophylactic-gastrostomy-locally-advanced-head-and-neck-cancer-results-national-survey-among 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/prophylactic-gastrostomy-locally-advanced-head-and-neck-cancer-results-national-survey-among 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/prophylactic-gastrostomy-locally-advanced-head-and-neck-cancer-results-national-survey-among 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/cross-talk-between-mesenchymal-stromal-cells-mscs-and-endothelial-progenitor-cells-epcs-bone 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/cross-talk-between-mesenchymal-stromal-cells-mscs-and-endothelial-progenitor-cells-epcs-bone 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/cross-talk-between-mesenchymal-stromal-cells-mscs-and-endothelial-progenitor-cells-epcs-bone 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/epithelioid-hemangioendothelioma-ultra-rare-cancer-consensus-paper-community-experts 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/epithelioid-hemangioendothelioma-ultra-rare-cancer-consensus-paper-community-experts 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/epithelioid-hemangioendothelioma-ultra-rare-cancer-consensus-paper-community-experts 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/adjuvant-olaparib-patients-brca1-or-brca2-mutated-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/adjuvant-olaparib-patients-brca1-or-brca2-mutated-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/adjuvant-olaparib-patients-brca1-or-brca2-mutated-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/staggered-enforcement-infection-control-and-prevention-measures-following-four-consecutive 2021-06-14T07:00:19+02:00 0.5 https://bordet.makemeweb.dev/en/retrospective-analysis-chest-ct-imaging-findings-covid-19-cancer-patients-initial-experience 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/retrospective-analysis-chest-ct-imaging-findings-covid-19-cancer-patients-initial-experience 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/retrospective-analysis-chest-ct-imaging-findings-covid-19-cancer-patients-initial-experience 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/allo-les-soignants-ici-la-covid-qui-vous-parle-kairos-revue-thematique-palliative-de-brusano 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/allo-les-soignants-ici-la-covid-qui-vous-parle-kairos-revue-thematique-palliative-de-brusano 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/allo-les-soignants-ici-la-covid-qui-vous-parle-kairos-revue-thematique-palliative-de-brusano 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/le-psy-hospitalier-dans-la-tourmente-du-covid-19-un-travail-en-suspension-psy-dans-l-urgence 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/le-psy-hospitalier-dans-la-tourmente-du-covid-19-un-travail-en-suspension-psy-dans-l-urgence 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/le-psy-hospitalier-dans-la-tourmente-du-covid-19-un-travail-en-suspension-psy-dans-l-urgence 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/line-field-confocal-optical-coherence-tomography-actinic-keratosis-and-squamous-cell-carcinoma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/line-field-confocal-optical-coherence-tomography-actinic-keratosis-and-squamous-cell-carcinoma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/line-field-confocal-optical-coherence-tomography-actinic-keratosis-and-squamous-cell-carcinoma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/biomarker-analyses-phase-iii-ascent-study-sacituzumab-govitecan-versus-chemotherapy-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/biomarker-analyses-phase-iii-ascent-study-sacituzumab-govitecan-versus-chemotherapy-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/biomarker-analyses-phase-iii-ascent-study-sacituzumab-govitecan-versus-chemotherapy-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/line-field-confocal-optical-coherence-tomography-non-invasive-diagnosis-lichenoid-dermatoses 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/line-field-confocal-optical-coherence-tomography-non-invasive-diagnosis-lichenoid-dermatoses 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/line-field-confocal-optical-coherence-tomography-non-invasive-diagnosis-lichenoid-dermatoses 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/targeted-agents-older-patients-gastrointestinal-cancers-overview 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/targeted-agents-older-patients-gastrointestinal-cancers-overview 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/targeted-agents-older-patients-gastrointestinal-cancers-overview 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/outcomes-and-prognostic-factors-large-cohort-hospitalized-cancer-patients-covid-19 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/outcomes-and-prognostic-factors-large-cohort-hospitalized-cancer-patients-covid-19 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/outcomes-and-prognostic-factors-large-cohort-hospitalized-cancer-patients-covid-19 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/antibodies-targeting-prostate-specific-membrane-antigen-positive-prostate-cancer-diagnostic-imaging 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/antibodies-targeting-prostate-specific-membrane-antigen-positive-prostate-cancer-diagnostic-imaging 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/antibodies-targeting-prostate-specific-membrane-antigen-positive-prostate-cancer-diagnostic-imaging 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/histological-growth-pattern-and-clinico-metabolic-characteristics-accurately-predict-outcome 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/histological-growth-pattern-and-clinico-metabolic-characteristics-accurately-predict-outcome 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/histological-growth-pattern-and-clinico-metabolic-characteristics-accurately-predict-outcome 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/biological-and-clinical-features-triple-negative-invasive-lobular-carcinomas-breast-clinical 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/biological-and-clinical-features-triple-negative-invasive-lobular-carcinomas-breast-clinical 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/biological-and-clinical-features-triple-negative-invasive-lobular-carcinomas-breast-clinical 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/pregnancy-after-breast-cancer-systematic-review-and-meta-analysis 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/pregnancy-after-breast-cancer-systematic-review-and-meta-analysis 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/pregnancy-after-breast-cancer-systematic-review-and-meta-analysis 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/buschke-lowenstein-tumor-human-immunodeficiency-virus-positive-patient-case-report-and-short 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/buschke-lowenstein-tumor-human-immunodeficiency-virus-positive-patient-case-report-and-short 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/buschke-lowenstein-tumor-human-immunodeficiency-virus-positive-patient-case-report-and-short 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/endovascular-retroperitoneoscopic-aortobifemoral-bypass-reasonable-alternative-transperitoneal-open 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/endovascular-retroperitoneoscopic-aortobifemoral-bypass-reasonable-alternative-transperitoneal-open 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/endovascular-retroperitoneoscopic-aortobifemoral-bypass-reasonable-alternative-transperitoneal-open 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/primary-antibiotic-resistance-helicobacter-pylori-isolates-twofold-more-frequent-hiv-positive-hiv 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/primary-antibiotic-resistance-helicobacter-pylori-isolates-twofold-more-frequent-hiv-positive-hiv 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/primary-antibiotic-resistance-helicobacter-pylori-isolates-twofold-more-frequent-hiv-positive-hiv 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/genomic-and-transcriptomic-analyses-breast-cancer-primaries-and-matched-metastases-aurora-breast 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/genomic-and-transcriptomic-analyses-breast-cancer-primaries-and-matched-metastases-aurora-breast 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/genomic-and-transcriptomic-analyses-breast-cancer-primaries-and-matched-metastases-aurora-breast 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/interobserver-variability-organ-risk-delineation-head-and-neck-cancer 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/interobserver-variability-organ-risk-delineation-head-and-neck-cancer 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/interobserver-variability-organ-risk-delineation-head-and-neck-cancer 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/vista-promising-target-cancer-immunotherapy 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/vista-promising-target-cancer-immunotherapy 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/vista-promising-target-cancer-immunotherapy 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/nhancer-mutation-equipped-anti-met-antibody-argx-111-displays-increased-tissue-penetration-and-anti 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/nhancer-mutation-equipped-anti-met-antibody-argx-111-displays-increased-tissue-penetration-and-anti 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/nhancer-mutation-equipped-anti-met-antibody-argx-111-displays-increased-tissue-penetration-and-anti 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/jaundice-and-double-duct-sign-always-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/jaundice-and-double-duct-sign-always-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/jaundice-and-double-duct-sign-always-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/her2-low-breast-cancer-molecular-characteristics-and-prognosis 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/her2-low-breast-cancer-molecular-characteristics-and-prognosis 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/her2-low-breast-cancer-molecular-characteristics-and-prognosis 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/targeted-radionuclide-therapy-emerging-field-solid-tumours 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/targeted-radionuclide-therapy-emerging-field-solid-tumours 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/targeted-radionuclide-therapy-emerging-field-solid-tumours 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/helminth-infection-induces-non-functional-sensitization-house-dust-mites 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/helminth-infection-induces-non-functional-sensitization-house-dust-mites 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/helminth-infection-induces-non-functional-sensitization-house-dust-mites 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/emerging-issues-related-covid-19-vaccination-patients-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/emerging-issues-related-covid-19-vaccination-patients-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/emerging-issues-related-covid-19-vaccination-patients-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/mixed-method-study-design-explore-adherence-haematological-cancer-patients-oral-anticancer 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/mixed-method-study-design-explore-adherence-haematological-cancer-patients-oral-anticancer 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/mixed-method-study-design-explore-adherence-haematological-cancer-patients-oral-anticancer 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/risk-based-decision-making-treatment-her2-positive-early-breast-cancer-recommendations-based 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/risk-based-decision-making-treatment-her2-positive-early-breast-cancer-recommendations-based 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/risk-based-decision-making-treatment-her2-positive-early-breast-cancer-recommendations-based 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/clinicopathologic-spectrum-and-genomic-landscape-de-trans-differentiated-melanoma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/clinicopathologic-spectrum-and-genomic-landscape-de-trans-differentiated-melanoma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/clinicopathologic-spectrum-and-genomic-landscape-de-trans-differentiated-melanoma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/allogeneic-hematopoietic-cell-transplantation-older-myelofibrosis-patients-study-chronic 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/allogeneic-hematopoietic-cell-transplantation-older-myelofibrosis-patients-study-chronic 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/allogeneic-hematopoietic-cell-transplantation-older-myelofibrosis-patients-study-chronic 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/complete-response-and-renal-cell-carcinoma-immunotherapy-era-paradox-good-news 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/complete-response-and-renal-cell-carcinoma-immunotherapy-era-paradox-good-news 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/complete-response-and-renal-cell-carcinoma-immunotherapy-era-paradox-good-news 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/late-dermatologic-presentation-bullous-pemphigoid-induced-anti-pd-1-therapy-and-associated 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/late-dermatologic-presentation-bullous-pemphigoid-induced-anti-pd-1-therapy-and-associated 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/late-dermatologic-presentation-bullous-pemphigoid-induced-anti-pd-1-therapy-and-associated 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/european-cancer-organisation-essential-requirements-quality-cancer-care-erqcc-pancreatic-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/european-cancer-organisation-essential-requirements-quality-cancer-care-erqcc-pancreatic-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/european-cancer-organisation-essential-requirements-quality-cancer-care-erqcc-pancreatic-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/pristine-submucosal-visibility-using-texture-and-color-enhancement-imaging-during-saline-immersion 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/pristine-submucosal-visibility-using-texture-and-color-enhancement-imaging-during-saline-immersion 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/pristine-submucosal-visibility-using-texture-and-color-enhancement-imaging-during-saline-immersion 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/correction-performance-rox-index-predict-intubation-immunocompromised-patients-receiving-high-flow 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/correction-performance-rox-index-predict-intubation-immunocompromised-patients-receiving-high-flow 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/correction-performance-rox-index-predict-intubation-immunocompromised-patients-receiving-high-flow 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/microbiome-mediator-diet-colorectal-cancer-risk-role-vitamin-d-markers-inflammation-and-adipokines 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/microbiome-mediator-diet-colorectal-cancer-risk-role-vitamin-d-markers-inflammation-and-adipokines 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/microbiome-mediator-diet-colorectal-cancer-risk-role-vitamin-d-markers-inflammation-and-adipokines 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/discovery-and-3d-imaging-novel-np63-expressing-basal-cell-type-human-pancreatic-ducts-implications 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/discovery-and-3d-imaging-novel-np63-expressing-basal-cell-type-human-pancreatic-ducts-implications 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/discovery-and-3d-imaging-novel-np63-expressing-basal-cell-type-human-pancreatic-ducts-implications 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/response-letter-entitled-re-cardiotoxicity-immune-checkpoint-inhibitors-systematic-review-and-meta 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/response-letter-entitled-re-cardiotoxicity-immune-checkpoint-inhibitors-systematic-review-and-meta 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/response-letter-entitled-re-cardiotoxicity-immune-checkpoint-inhibitors-systematic-review-and-meta 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/continuous-versus-intermittent-extended-adjuvant-letrozole-breast-cancer-final-results-randomized 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/continuous-versus-intermittent-extended-adjuvant-letrozole-breast-cancer-final-results-randomized 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/continuous-versus-intermittent-extended-adjuvant-letrozole-breast-cancer-final-results-randomized 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/mir-7-5p-inhibits-thyroid-cell-proliferation-targeting-egfrmapk-and-irs2pi3k-signaling-pathways 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/mir-7-5p-inhibits-thyroid-cell-proliferation-targeting-egfrmapk-and-irs2pi3k-signaling-pathways 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/mir-7-5p-inhibits-thyroid-cell-proliferation-targeting-egfrmapk-and-irs2pi3k-signaling-pathways 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/staggered-enforcement-infection-control-and-prevention-measures-following-four-consecutive 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/staggered-enforcement-infection-control-and-prevention-measures-following-four-consecutive-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/staggered-enforcement-infection-control-and-prevention-measures-following-four-consecutive 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/neo-checkray-radiation-therapy-and-adenosine-pathway-blockade-increase-benefit-immuno-chemotherapy 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/neo-checkray-radiation-therapy-and-adenosine-pathway-blockade-increase-benefit-immuno-chemotherapy 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/neo-checkray-radiation-therapy-and-adenosine-pathway-blockade-increase-benefit-immuno-chemotherapy 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/outcomes-icu-patients-and-without-perceptions-excessive-care-comparison-between-cancer-and-non 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/outcomes-icu-patients-and-without-perceptions-excessive-care-comparison-between-cancer-and-non 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/outcomes-icu-patients-and-without-perceptions-excessive-care-comparison-between-cancer-and-non 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/sexual-dysfunction-due-pudendal-neuralgia-systematic-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/sexual-dysfunction-due-pudendal-neuralgia-systematic-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/sexual-dysfunction-due-pudendal-neuralgia-systematic-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/who-are-women-who-enrolled-positive-trial-global-study-support-young-hormone-receptor-positive 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/who-are-women-who-enrolled-positive-trial-global-study-support-young-hormone-receptor-positive 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/who-are-women-who-enrolled-positive-trial-global-study-support-young-hormone-receptor-positive 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/apoptotic-and-non-apoptotic-modalities-thymoquinone-induced-lymphoma-cell-death-highlight-role 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/apoptotic-and-non-apoptotic-modalities-thymoquinone-induced-lymphoma-cell-death-highlight-role 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/apoptotic-and-non-apoptotic-modalities-thymoquinone-induced-lymphoma-cell-death-highlight-role 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/pathological-features-prostate-imaging-reporting-and-data-system-pi-rads-3-mri-lesions-biopsy-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/pathological-features-prostate-imaging-reporting-and-data-system-pi-rads-3-mri-lesions-biopsy-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/pathological-features-prostate-imaging-reporting-and-data-system-pi-rads-3-mri-lesions-biopsy-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/tumour-infiltrating-lymphocytes-non-invasive-breast-cancer-systematic-review-and-meta-analysis 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/tumour-infiltrating-lymphocytes-non-invasive-breast-cancer-systematic-review-and-meta-analysis 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/tumour-infiltrating-lymphocytes-non-invasive-breast-cancer-systematic-review-and-meta-analysis 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/copy-number-aberration-analysis-predict-response-neoadjuvant-anti-her2-therapy-results-neoaltto 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/copy-number-aberration-analysis-predict-response-neoadjuvant-anti-her2-therapy-results-neoaltto 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/copy-number-aberration-analysis-predict-response-neoadjuvant-anti-her2-therapy-results-neoaltto 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/right-ventricular-longitudinal-fractional-shortening-substitute-right-ventricular-free-wall 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/right-ventricular-longitudinal-fractional-shortening-substitute-right-ventricular-free-wall 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/right-ventricular-longitudinal-fractional-shortening-substitute-right-ventricular-free-wall 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/combined-metabolically-active-tumor-volume-and-early-metabolic-response-improve-outcome-prediction 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/combined-metabolically-active-tumor-volume-and-early-metabolic-response-improve-outcome-prediction 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/combined-metabolically-active-tumor-volume-and-early-metabolic-response-improve-outcome-prediction 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/survival-among-patients-relapsedrefractory-diffuse-large-b-cell-lymphoma-treated-single-agent 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/survival-among-patients-relapsedrefractory-diffuse-large-b-cell-lymphoma-treated-single-agent 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/survival-among-patients-relapsedrefractory-diffuse-large-b-cell-lymphoma-treated-single-agent 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/soft-tissue-and-visceral-sarcomas-esmo-euracan-genturis-clinical-practice-guidelines-diagnosis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/soft-tissue-and-visceral-sarcomas-esmo-euracan-genturis-clinical-practice-guidelines-diagnosis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/soft-tissue-and-visceral-sarcomas-esmo-euracan-genturis-clinical-practice-guidelines-diagnosis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/eano-esmo-clinical-practice-guidelines-diagnosis-treatment-and-follow-patients-brain-metastasis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/eano-esmo-clinical-practice-guidelines-diagnosis-treatment-and-follow-patients-brain-metastasis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/eano-esmo-clinical-practice-guidelines-diagnosis-treatment-and-follow-patients-brain-metastasis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/line-field-confocal-optical-coherence-tomography-actinic-keratosis-case-series 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/line-field-confocal-optical-coherence-tomography-actinic-keratosis-case-series 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/line-field-confocal-optical-coherence-tomography-actinic-keratosis-case-series 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/sars-cov-2-infection-hematological-patients-during-allogenic-stem-cell-transplantation-double-case 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/sars-cov-2-infection-hematological-patients-during-allogenic-stem-cell-transplantation-double-case 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/sars-cov-2-infection-hematological-patients-during-allogenic-stem-cell-transplantation-double-case 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/transcriptional-profile-cytokines-regulatory-mediators-and-tlr-mesenchymal-stromal-cells-after 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/transcriptional-profile-cytokines-regulatory-mediators-and-tlr-mesenchymal-stromal-cells-after 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/transcriptional-profile-cytokines-regulatory-mediators-and-tlr-mesenchymal-stromal-cells-after 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/analyses-rationale-and-implementation-research-biopsies-oncology-clinical-trials-tertiary-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/analyses-rationale-and-implementation-research-biopsies-oncology-clinical-trials-tertiary-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/analyses-rationale-and-implementation-research-biopsies-oncology-clinical-trials-tertiary-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/niraparib-advanced-breast-cancer-germline-brca1-and-brca2-mutations-eortc-1307-bcgbig5-13tesaro-pr 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/niraparib-advanced-breast-cancer-germline-brca1-and-brca2-mutations-eortc-1307-bcgbig5-13tesaro-pr 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/niraparib-advanced-breast-cancer-germline-brca1-and-brca2-mutations-eortc-1307-bcgbig5-13tesaro-pr 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/characterization-and-clinical-utility-brafv600-mutation-detection-using-cell-free-dna-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/characterization-and-clinical-utility-brafv600-mutation-detection-using-cell-free-dna-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/characterization-and-clinical-utility-brafv600-mutation-detection-using-cell-free-dna-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/assessment-potential-process-quality-indicators-systemic-treatment-breast-cancer-belgium-population 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/assessment-potential-process-quality-indicators-systemic-treatment-breast-cancer-belgium-population 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/assessment-potential-process-quality-indicators-systemic-treatment-breast-cancer-belgium-population 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/new-horizons-early-drugs-development-solid-cancers 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/new-horizons-early-drugs-development-solid-cancers 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/new-horizons-early-drugs-development-solid-cancers 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/additional-value-18f-fdopa-amino-acid-analog-radiotracer-irradiation-planning-process-patients 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/additional-value-18f-fdopa-amino-acid-analog-radiotracer-irradiation-planning-process-patients 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/additional-value-18f-fdopa-amino-acid-analog-radiotracer-irradiation-planning-process-patients 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/osteoid-osteoma-unique-presentation-child-s-lesser-toe 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/osteoid-osteoma-unique-presentation-child-s-lesser-toe 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/osteoid-osteoma-unique-presentation-child-s-lesser-toe 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/brca-mutant-pancreatic-ductal-adenocarcinoma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/brca-mutant-pancreatic-ductal-adenocarcinoma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/brca-mutant-pancreatic-ductal-adenocarcinoma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/cell-free-circulating-tumor-dna-profiling-cancer-management 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/cell-free-circulating-tumor-dna-profiling-cancer-management 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/cell-free-circulating-tumor-dna-profiling-cancer-management 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/sex-and-regorafenib-toxicity-refractory-colorectal-cancer-safety-analysis-regard-c-trial 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/sex-and-regorafenib-toxicity-refractory-colorectal-cancer-safety-analysis-regard-c-trial 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/sex-and-regorafenib-toxicity-refractory-colorectal-cancer-safety-analysis-regard-c-trial 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/contemporary-management-benign-uretero-enteric-strictures-after-cystectomy-systematic-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/contemporary-management-benign-uretero-enteric-strictures-after-cystectomy-systematic-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/contemporary-management-benign-uretero-enteric-strictures-after-cystectomy-systematic-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/dose-calculation-validation-convolution-algorithm-solid-water-phantom 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/dose-calculation-validation-convolution-algorithm-solid-water-phantom 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/dose-calculation-validation-convolution-algorithm-solid-water-phantom 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/value-one-additional-injection-root-limb-lymphoscintigraphic-evaluation-and-management-primary-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/value-one-additional-injection-root-limb-lymphoscintigraphic-evaluation-and-management-primary-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/value-one-additional-injection-root-limb-lymphoscintigraphic-evaluation-and-management-primary-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/methionine-pet-targeting-gamma-knife-radiosurgery-used-treat-recurrent-malignant-gliomas-inoperable 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/methionine-pet-targeting-gamma-knife-radiosurgery-used-treat-recurrent-malignant-gliomas-inoperable 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/methionine-pet-targeting-gamma-knife-radiosurgery-used-treat-recurrent-malignant-gliomas-inoperable 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/intestinal-presentation-non-hodgkin-lymphoma-case-report 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/intestinal-presentation-non-hodgkin-lymphoma-case-report 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/intestinal-presentation-non-hodgkin-lymphoma-case-report 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/hepatosplenic-t-cell-lymphoma-treatment-challenges 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/hepatosplenic-t-cell-lymphoma-treatment-challenges 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/hepatosplenic-t-cell-lymphoma-treatment-challenges 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/retrospective-validation-coverage-probability-based-simultaneous-integrated-nodal-boost-locally 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/retrospective-validation-coverage-probability-based-simultaneous-integrated-nodal-boost-locally 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/retrospective-validation-coverage-probability-based-simultaneous-integrated-nodal-boost-locally 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/beyond-lessons-learned-covid-19-pandemic-opportunities-optimize-clinical-trial-implementation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/beyond-lessons-learned-covid-19-pandemic-opportunities-optimize-clinical-trial-implementation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/beyond-lessons-learned-covid-19-pandemic-opportunities-optimize-clinical-trial-implementation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/oligometastatic-non-small-cell-lung-cancer-biology-clinical-practice 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/oligometastatic-non-small-cell-lung-cancer-biology-clinical-practice 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/oligometastatic-non-small-cell-lung-cancer-biology-clinical-practice 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/current-and-future-research-efforts-oligometastatic-non-small-cell-lung-cancer-systematic-review 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/current-and-future-research-efforts-oligometastatic-non-small-cell-lung-cancer-systematic-review 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/current-and-future-research-efforts-oligometastatic-non-small-cell-lung-cancer-systematic-review 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/circulating-tumor-dna-interrogate-safety-letrozole-associated-controlled-ovarian-stimulation 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/circulating-tumor-dna-interrogate-safety-letrozole-associated-controlled-ovarian-stimulation 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/circulating-tumor-dna-interrogate-safety-letrozole-associated-controlled-ovarian-stimulation 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/role-imaging-diagnosis-and-management-aortic-valve-papillary-fibroelastoma-and-cardiac-amyloid 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/role-imaging-diagnosis-and-management-aortic-valve-papillary-fibroelastoma-and-cardiac-amyloid 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/role-imaging-diagnosis-and-management-aortic-valve-papillary-fibroelastoma-and-cardiac-amyloid 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/peritoneal-patch-vascular-reconstruction-during-pancreaticoduodenectomy-pancreatic-cancer-single 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/peritoneal-patch-vascular-reconstruction-during-pancreaticoduodenectomy-pancreatic-cancer-single 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/peritoneal-patch-vascular-reconstruction-during-pancreaticoduodenectomy-pancreatic-cancer-single 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/fecal-microbiota-transplantation-immunotherapy-resistant-urological-tumors-it-time-update-recent 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/fecal-microbiota-transplantation-immunotherapy-resistant-urological-tumors-it-time-update-recent 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/fecal-microbiota-transplantation-immunotherapy-resistant-urological-tumors-it-time-update-recent 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/bone-sarcomas-esmo-euracan-genturis-ern-paedcan-clinical-practice-guideline-diagnosis-treatment-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/bone-sarcomas-esmo-euracan-genturis-ern-paedcan-clinical-practice-guideline-diagnosis-treatment-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/bone-sarcomas-esmo-euracan-genturis-ern-paedcan-clinical-practice-guideline-diagnosis-treatment-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/plain-language-summary-ascent-study-sacituzumab-govitecan-metastatic-triple-negative-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/plain-language-summary-ascent-study-sacituzumab-govitecan-metastatic-triple-negative-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/plain-language-summary-ascent-study-sacituzumab-govitecan-metastatic-triple-negative-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/therapeutic-potential-mesenchymal-stromal-cells-regenerative-medicine-current-knowledge-and-future 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/therapeutic-potential-mesenchymal-stromal-cells-regenerative-medicine-current-knowledge-and-future 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/therapeutic-potential-mesenchymal-stromal-cells-regenerative-medicine-current-knowledge-and-future 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/specialist-palliative-and-end-life-care-patients-cancer-and-sars-cov-2-infection-european 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/specialist-palliative-and-end-life-care-patients-cancer-and-sars-cov-2-infection-european 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/specialist-palliative-and-end-life-care-patients-cancer-and-sars-cov-2-infection-european 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/myths-superstitions-and-popular-beliefs-do-they-still-impact-our-practice 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/myths-superstitions-and-popular-beliefs-do-they-still-impact-our-practice 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/myths-superstitions-and-popular-beliefs-do-they-still-impact-our-practice 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/quality-life-analyses-patients-multiple-myeloma-results-selinexor-kpt-330-treatment-refractory 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/quality-life-analyses-patients-multiple-myeloma-results-selinexor-kpt-330-treatment-refractory 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/quality-life-analyses-patients-multiple-myeloma-results-selinexor-kpt-330-treatment-refractory 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/alpha-smooth-muscle-actin-expression-stroma-predicts-resistance-trastuzumab-patients-early-stage 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/alpha-smooth-muscle-actin-expression-stroma-predicts-resistance-trastuzumab-patients-early-stage 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/alpha-smooth-muscle-actin-expression-stroma-predicts-resistance-trastuzumab-patients-early-stage 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/increase-urolithiasis-prevalence-due-vitamins-c-and-d-supplementation-during-covid-19-pandemic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/increase-urolithiasis-prevalence-due-vitamins-c-and-d-supplementation-during-covid-19-pandemic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/increase-urolithiasis-prevalence-due-vitamins-c-and-d-supplementation-during-covid-19-pandemic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/efficacy-immune-checkpoint-inhibitors-upper-tract-urothelial-carcinomas-current-knowledge-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/efficacy-immune-checkpoint-inhibitors-upper-tract-urothelial-carcinomas-current-knowledge-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/efficacy-immune-checkpoint-inhibitors-upper-tract-urothelial-carcinomas-current-knowledge-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/comparison-effectiveness-and-safety-oral-selective-inhibitor-nuclear-export-selinexor-diffuse-large 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/comparison-effectiveness-and-safety-oral-selective-inhibitor-nuclear-export-selinexor-diffuse-large 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/comparison-effectiveness-and-safety-oral-selective-inhibitor-nuclear-export-selinexor-diffuse-large 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/anthracyclines-strike-back-rediscovering-non-pegylated-liposomal-doxorubicin-current-therapeutic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/anthracyclines-strike-back-rediscovering-non-pegylated-liposomal-doxorubicin-current-therapeutic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/anthracyclines-strike-back-rediscovering-non-pegylated-liposomal-doxorubicin-current-therapeutic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/prediction-imminent-fracture-after-index-fracture-models-derived-frisbee-cohort 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/prediction-imminent-fracture-after-index-fracture-models-derived-frisbee-cohort 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/prediction-imminent-fracture-after-index-fracture-models-derived-frisbee-cohort 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/focal-therapy-prostate-cancer-making-punishment-fit-crime 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/focal-therapy-prostate-cancer-making-punishment-fit-crime 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/focal-therapy-prostate-cancer-making-punishment-fit-crime 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/maintenance-daratumumab-or-observation-following-treatment-bortezomib-thalidomide-and-dexamethasone 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/maintenance-daratumumab-or-observation-following-treatment-bortezomib-thalidomide-and-dexamethasone 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/maintenance-daratumumab-or-observation-following-treatment-bortezomib-thalidomide-and-dexamethasone 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/integrated-molecular-and-immune-phenotype-her2-positive-breast-cancer-and-response-neoadjuvant 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/integrated-molecular-and-immune-phenotype-her2-positive-breast-cancer-and-response-neoadjuvant 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/integrated-molecular-and-immune-phenotype-her2-positive-breast-cancer-and-response-neoadjuvant 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/htlv-1-viral-oncoproteins-tax-and-hbz-reprogram-cellular-mrna-splicing-landscape 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/htlv-1-viral-oncoproteins-tax-and-hbz-reprogram-cellular-mrna-splicing-landscape 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/htlv-1-viral-oncoproteins-tax-and-hbz-reprogram-cellular-mrna-splicing-landscape 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/role-postoperative-radiotherapy-management-resected-nsclc-decision-criteria-clinical-routine-pre 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/role-postoperative-radiotherapy-management-resected-nsclc-decision-criteria-clinical-routine-pre 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/role-postoperative-radiotherapy-management-resected-nsclc-decision-criteria-clinical-routine-pre 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/role-prostate-specific-membrane-antigen-positron-emission-tomographymagnetic-resonance-imaging 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/role-prostate-specific-membrane-antigen-positron-emission-tomographymagnetic-resonance-imaging 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/role-prostate-specific-membrane-antigen-positron-emission-tomographymagnetic-resonance-imaging 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/prognostic-significance-scoring-system-combining-p16-smoking-and-drinking-status-series-131 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/prognostic-significance-scoring-system-combining-p16-smoking-and-drinking-status-series-131 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/prognostic-significance-scoring-system-combining-p16-smoking-and-drinking-status-series-131 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/gastrointestinal-stromal-tumours-esmo-euracan-genturis-clinical-practice-guidelines-diagnosis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/gastrointestinal-stromal-tumours-esmo-euracan-genturis-clinical-practice-guidelines-diagnosis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/gastrointestinal-stromal-tumours-esmo-euracan-genturis-clinical-practice-guidelines-diagnosis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/effect-salivary-bypass-tube-use-prevention-pharyngo-cutaneous-fistulas-after-total-laryngectomy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/effect-salivary-bypass-tube-use-prevention-pharyngo-cutaneous-fistulas-after-total-laryngectomy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/effect-salivary-bypass-tube-use-prevention-pharyngo-cutaneous-fistulas-after-total-laryngectomy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/lung-cancer-belgium 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/lung-cancer-belgium 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/lung-cancer-belgium 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/critically-ill-cancer-patient-s-resuscitation-belgianfrench-societies-consensus-conference 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/critically-ill-cancer-patient-s-resuscitation-belgianfrench-societies-consensus-conference 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/critically-ill-cancer-patient-s-resuscitation-belgianfrench-societies-consensus-conference 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/independent-external-validation-frax-and-garvan-fracture-risk-calculators-sub-study-frisbee-cohort 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/independent-external-validation-frax-and-garvan-fracture-risk-calculators-sub-study-frisbee-cohort 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/independent-external-validation-frax-and-garvan-fracture-risk-calculators-sub-study-frisbee-cohort 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/fdg-positron-emission-tomography-imaging-and-ctdna-detection-early-dynamic-biomarker-everolimus 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/fdg-positron-emission-tomography-imaging-and-ctdna-detection-early-dynamic-biomarker-everolimus 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/fdg-positron-emission-tomography-imaging-and-ctdna-detection-early-dynamic-biomarker-everolimus 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/tackling-refractory-metastatic-colorectal-cancer-future-perspectives 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/tackling-refractory-metastatic-colorectal-cancer-future-perspectives 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/tackling-refractory-metastatic-colorectal-cancer-future-perspectives 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/brazilian-validation-european-organisation-research-and-treatment-cancer-eortc-quality-life-group 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/brazilian-validation-european-organisation-research-and-treatment-cancer-eortc-quality-life-group 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/brazilian-validation-european-organisation-research-and-treatment-cancer-eortc-quality-life-group 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/line-field-confocal-optical-coherence-tomography-case-importance-full-lesion-examination-basal-cell 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/line-field-confocal-optical-coherence-tomography-case-importance-full-lesion-examination-basal-cell 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/line-field-confocal-optical-coherence-tomography-case-importance-full-lesion-examination-basal-cell 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/lessons-learned-about-appendiceal-neuroendocrine-neoplasms-data-analysis-belgian-cancer-registry 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/lessons-learned-about-appendiceal-neuroendocrine-neoplasms-data-analysis-belgian-cancer-registry 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/lessons-learned-about-appendiceal-neuroendocrine-neoplasms-data-analysis-belgian-cancer-registry 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/giant-parastomal-hernia-high-risk-patient-preparation-make-surgery-worthwhile 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/giant-parastomal-hernia-high-risk-patient-preparation-make-surgery-worthwhile 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/giant-parastomal-hernia-high-risk-patient-preparation-make-surgery-worthwhile 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/b-cells-and-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/b-cells-and-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/b-cells-and-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/accuracy-and-other-quality-indicators-solid-pancreatic-mass-endoscopic-ultrasound-guided-fine 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/accuracy-and-other-quality-indicators-solid-pancreatic-mass-endoscopic-ultrasound-guided-fine 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/accuracy-and-other-quality-indicators-solid-pancreatic-mass-endoscopic-ultrasound-guided-fine 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/continuing-acetylsalicylic-acid-during-robotic-assisted-radical-cystectomy-intracorporeal-urinary 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/continuing-acetylsalicylic-acid-during-robotic-assisted-radical-cystectomy-intracorporeal-urinary 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/continuing-acetylsalicylic-acid-during-robotic-assisted-radical-cystectomy-intracorporeal-urinary 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/unusual-nasopharyngeal-polyp 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/unusual-nasopharyngeal-polyp 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/unusual-nasopharyngeal-polyp 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/first-line-nivolumab-plus-low-dose-ipilimumab-microsatellite-instability-highmismatch-repair 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/first-line-nivolumab-plus-low-dose-ipilimumab-microsatellite-instability-highmismatch-repair 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/first-line-nivolumab-plus-low-dose-ipilimumab-microsatellite-instability-highmismatch-repair 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/quality-pathology-reporting-and-adherence-guidelines-rectal-neuroendocrine-neoplasms-belgian 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/quality-pathology-reporting-and-adherence-guidelines-rectal-neuroendocrine-neoplasms-belgian 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/quality-pathology-reporting-and-adherence-guidelines-rectal-neuroendocrine-neoplasms-belgian 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/correction-tolerability-and-toxicity-trastuzumab-or-trastuzumab-lapatinib-older-patients-sub 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/correction-tolerability-and-toxicity-trastuzumab-or-trastuzumab-lapatinib-older-patients-sub 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/correction-tolerability-and-toxicity-trastuzumab-or-trastuzumab-lapatinib-older-patients-sub 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/sequential-administration-low-dose-5-azacytidine-aza-and-donor-lymphocyte-infusion-dli-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/sequential-administration-low-dose-5-azacytidine-aza-and-donor-lymphocyte-infusion-dli-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/sequential-administration-low-dose-5-azacytidine-aza-and-donor-lymphocyte-infusion-dli-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/fluorescent-multiplex-immunohistochemistry-coupled-other-state-art-techniques-systematically 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/fluorescent-multiplex-immunohistochemistry-coupled-other-state-art-techniques-systematically 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/fluorescent-multiplex-immunohistochemistry-coupled-other-state-art-techniques-systematically 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/line-field-confocal-optical-coherence-tomography-tool-three-dimensional-vivo-quantification-healthy 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/line-field-confocal-optical-coherence-tomography-tool-three-dimensional-vivo-quantification-healthy 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/line-field-confocal-optical-coherence-tomography-tool-three-dimensional-vivo-quantification-healthy 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/review-immune-checkpoint-blockade-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/review-immune-checkpoint-blockade-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/review-immune-checkpoint-blockade-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/fuscrem-rearranged-malignant-epithelioid-neoplasm-mimicking-neuroendocrine-neoplasm-unknown-primary 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/fuscrem-rearranged-malignant-epithelioid-neoplasm-mimicking-neuroendocrine-neoplasm-unknown-primary 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/fuscrem-rearranged-malignant-epithelioid-neoplasm-mimicking-neuroendocrine-neoplasm-unknown-primary 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/dosimetric-impact-intrafraction-motion-during-peripheral-lung-cancer-stereotactic-radiotherapy 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/dosimetric-impact-intrafraction-motion-during-peripheral-lung-cancer-stereotactic-radiotherapy 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/dosimetric-impact-intrafraction-motion-during-peripheral-lung-cancer-stereotactic-radiotherapy 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/non-invasive-imaging-rare-presentation-infantile-generalized-eruptive-histiocytosis-xanthogranuloma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/non-invasive-imaging-rare-presentation-infantile-generalized-eruptive-histiocytosis-xanthogranuloma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/non-invasive-imaging-rare-presentation-infantile-generalized-eruptive-histiocytosis-xanthogranuloma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/isotoxic-high-dose-stereotactic-body-radiotherapy-integrated-total-multimodal-neoadjuvant-strategy 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/isotoxic-high-dose-stereotactic-body-radiotherapy-integrated-total-multimodal-neoadjuvant-strategy 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/isotoxic-high-dose-stereotactic-body-radiotherapy-integrated-total-multimodal-neoadjuvant-strategy 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/everolimus-induced-somatostatin-receptor-overexpression-rectal-neuroendocrine-tumor-patient-may 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/everolimus-induced-somatostatin-receptor-overexpression-rectal-neuroendocrine-tumor-patient-may 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/everolimus-induced-somatostatin-receptor-overexpression-rectal-neuroendocrine-tumor-patient-may 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/esmo-clinical-practice-guideline-diagnosis-staging-and-treatment-patients-metastatic-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/esmo-clinical-practice-guideline-diagnosis-staging-and-treatment-patients-metastatic-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/esmo-clinical-practice-guideline-diagnosis-staging-and-treatment-patients-metastatic-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/neurological-complications-induced-immune-checkpoint-inhibitors-comprehensive-descriptive-case 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/neurological-complications-induced-immune-checkpoint-inhibitors-comprehensive-descriptive-case 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/neurological-complications-induced-immune-checkpoint-inhibitors-comprehensive-descriptive-case 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/high-prevalence-5t4trophoblast-glycoprotein-soft-tissue-sarcomas 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/high-prevalence-5t4trophoblast-glycoprotein-soft-tissue-sarcomas 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/high-prevalence-5t4trophoblast-glycoprotein-soft-tissue-sarcomas 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/oligometastatic-disease-detection-68ga-psma-11-petct-hormone-sensitive-prostate-cancer-patients 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/oligometastatic-disease-detection-68ga-psma-11-petct-hormone-sensitive-prostate-cancer-patients 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/oligometastatic-disease-detection-68ga-psma-11-petct-hormone-sensitive-prostate-cancer-patients 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/physiological-and-clinical-impact-repeated-inhaled-oxygen-variation-erythropoietin-levels-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/physiological-and-clinical-impact-repeated-inhaled-oxygen-variation-erythropoietin-levels-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/physiological-and-clinical-impact-repeated-inhaled-oxygen-variation-erythropoietin-levels-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/conquest-lung-cancer-central-europe 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/conquest-lung-cancer-central-europe 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/conquest-lung-cancer-central-europe 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/vitro-cellular-and-molecular-interplay-between-human-foreskin-derived-mesenchymal-stromalstem-cells 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/vitro-cellular-and-molecular-interplay-between-human-foreskin-derived-mesenchymal-stromalstem-cells 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/vitro-cellular-and-molecular-interplay-between-human-foreskin-derived-mesenchymal-stromalstem-cells 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/clinical-activity-and-safety-cabozantinib-brain-metastases-patients-renal-cell-carcinoma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/clinical-activity-and-safety-cabozantinib-brain-metastases-patients-renal-cell-carcinoma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/clinical-activity-and-safety-cabozantinib-brain-metastases-patients-renal-cell-carcinoma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/unintended-dose-lower-axilla-adjuvant-radiotherapy-breast-cancer-differences-between-tangential 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/unintended-dose-lower-axilla-adjuvant-radiotherapy-breast-cancer-differences-between-tangential 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/unintended-dose-lower-axilla-adjuvant-radiotherapy-breast-cancer-differences-between-tangential 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/carfilzomib-maintenance-newly-diagnosed-non-transplant-eligible-multiple-myeloma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/carfilzomib-maintenance-newly-diagnosed-non-transplant-eligible-multiple-myeloma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/carfilzomib-maintenance-newly-diagnosed-non-transplant-eligible-multiple-myeloma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/efficacy-and-safety-lanreotide-autogel-treatment-clinical-symptoms-associated-inoperable-malignant 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/efficacy-and-safety-lanreotide-autogel-treatment-clinical-symptoms-associated-inoperable-malignant 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/efficacy-and-safety-lanreotide-autogel-treatment-clinical-symptoms-associated-inoperable-malignant 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/impact-helicobacter-pylori-related-metabolic-syndrome-parameters-arterial-hypertension 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/impact-helicobacter-pylori-related-metabolic-syndrome-parameters-arterial-hypertension 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/impact-helicobacter-pylori-related-metabolic-syndrome-parameters-arterial-hypertension 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/time-dependent-covid-19-mortality-patients-cancer-updated-analysis-oncovid-registry 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/time-dependent-covid-19-mortality-patients-cancer-updated-analysis-oncovid-registry 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/time-dependent-covid-19-mortality-patients-cancer-updated-analysis-oncovid-registry 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/asymmetric-labium-majus-enlargement-adult-case-report 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/asymmetric-labium-majus-enlargement-adult-case-report 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/asymmetric-labium-majus-enlargement-adult-case-report 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/delineation-guidelines-lymphatic-target-volumes-prone-crawl-radiotherapy-treatment-position-breast 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/delineation-guidelines-lymphatic-target-volumes-prone-crawl-radiotherapy-treatment-position-breast 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/delineation-guidelines-lymphatic-target-volumes-prone-crawl-radiotherapy-treatment-position-breast 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/perspectives-emerging-technologies-personalised-medicine-and-clinical-research-cancer-control-latin 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/perspectives-emerging-technologies-personalised-medicine-and-clinical-research-cancer-control-latin 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/perspectives-emerging-technologies-personalised-medicine-and-clinical-research-cancer-control-latin 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/isolated-oesophageal-crohn-s-disease-mimicking-oesophageal-carcinoma-treated-merendino-procedure 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/isolated-oesophageal-crohn-s-disease-mimicking-oesophageal-carcinoma-treated-merendino-procedure 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/isolated-oesophageal-crohn-s-disease-mimicking-oesophageal-carcinoma-treated-merendino-procedure 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/lymphoscintigraphic-investigations-axillary-web-syndromes 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/lymphoscintigraphic-investigations-axillary-web-syndromes 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/lymphoscintigraphic-investigations-axillary-web-syndromes 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/de-novo-metastatic-breast-cancer-arising-young-women-review-current-evidence 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/de-novo-metastatic-breast-cancer-arising-young-women-review-current-evidence 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/de-novo-metastatic-breast-cancer-arising-young-women-review-current-evidence 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/covid-19-severity-and-mortality-patients-cll-update-international-eric-and-campus-cll-study 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/covid-19-severity-and-mortality-patients-cll-update-international-eric-and-campus-cll-study 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/covid-19-severity-and-mortality-patients-cll-update-international-eric-and-campus-cll-study 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/68ga-psma-petct-response-assessment-and-outcome-prediction-metastatic-prostate-cancer-patients 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/68ga-psma-petct-response-assessment-and-outcome-prediction-metastatic-prostate-cancer-patients 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/68ga-psma-petct-response-assessment-and-outcome-prediction-metastatic-prostate-cancer-patients 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/heterogeneity-circulating-tumor-cell-associated-genomic-gains-breast-cancer-and-its-association 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/heterogeneity-circulating-tumor-cell-associated-genomic-gains-breast-cancer-and-its-association 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/heterogeneity-circulating-tumor-cell-associated-genomic-gains-breast-cancer-and-its-association 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/endoscopic-duodenal-mucosal-resurfacing-nonalcoholic-steatohepatitis-nash-pilot-study 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/endoscopic-duodenal-mucosal-resurfacing-nonalcoholic-steatohepatitis-nash-pilot-study 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/endoscopic-duodenal-mucosal-resurfacing-nonalcoholic-steatohepatitis-nash-pilot-study 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/safety-assisted-reproductive-techniques-young-women-harboring-germline-pathogenic-variants-brca12 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/safety-assisted-reproductive-techniques-young-women-harboring-germline-pathogenic-variants-brca12 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/safety-assisted-reproductive-techniques-young-women-harboring-germline-pathogenic-variants-brca12 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/cusatuzumab-treatment-cd70-positive-relapsed-or-refractory-cutaneous-t-cell-lymphoma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/cusatuzumab-treatment-cd70-positive-relapsed-or-refractory-cutaneous-t-cell-lymphoma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/cusatuzumab-treatment-cd70-positive-relapsed-or-refractory-cutaneous-t-cell-lymphoma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/prevalence-and-impact-covid-19-sequelae-treatment-and-survival-patients-cancer-who-recovered-sars 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/prevalence-and-impact-covid-19-sequelae-treatment-and-survival-patients-cancer-who-recovered-sars 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/prevalence-and-impact-covid-19-sequelae-treatment-and-survival-patients-cancer-who-recovered-sars 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/robotic-partial-cystectomy-urachal-carcinoma-case-report-and-review-literature 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/robotic-partial-cystectomy-urachal-carcinoma-case-report-and-review-literature 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/robotic-partial-cystectomy-urachal-carcinoma-case-report-and-review-literature 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/thyroid-cancer-under-scope-emerging-technologies 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/thyroid-cancer-under-scope-emerging-technologies 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/thyroid-cancer-under-scope-emerging-technologies 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/tumor-suppressor-mirna-cancer-cells-and-tumor-microenvironment-mechanism-deregulation-and-clinical 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/tumor-suppressor-mirna-cancer-cells-and-tumor-microenvironment-mechanism-deregulation-and-clinical 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/tumor-suppressor-mirna-cancer-cells-and-tumor-microenvironment-mechanism-deregulation-and-clinical 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/anterior-vs-retzius-sparing-robotic-assisted-radical-prostatectomy-can-approach-really-make 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/anterior-vs-retzius-sparing-robotic-assisted-radical-prostatectomy-can-approach-really-make 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/anterior-vs-retzius-sparing-robotic-assisted-radical-prostatectomy-can-approach-really-make 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/procalung-peer-review-stage-iii-mediastinal-node-positive-non-small-cell-lung-cancer-how-benchmark 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/procalung-peer-review-stage-iii-mediastinal-node-positive-non-small-cell-lung-cancer-how-benchmark 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/procalung-peer-review-stage-iii-mediastinal-node-positive-non-small-cell-lung-cancer-how-benchmark 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/debating-pros-and-cons-total-neoadjuvant-therapy-rectal-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/debating-pros-and-cons-total-neoadjuvant-therapy-rectal-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/debating-pros-and-cons-total-neoadjuvant-therapy-rectal-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/cutaneous-lesions-anderson-fabry-disease-examined-novel-technique-line-field-confocal-optical 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/cutaneous-lesions-anderson-fabry-disease-examined-novel-technique-line-field-confocal-optical 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/cutaneous-lesions-anderson-fabry-disease-examined-novel-technique-line-field-confocal-optical 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/obinutuzumab-plus-lenalidomide-advanced-previously-untreated-follicular-lymphoma-need-systemic 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/obinutuzumab-plus-lenalidomide-advanced-previously-untreated-follicular-lymphoma-need-systemic 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/obinutuzumab-plus-lenalidomide-advanced-previously-untreated-follicular-lymphoma-need-systemic 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/implementation-fetal-clinical-exome-sequencing-comparing-prospective-and-retrospective-cohorts 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/implementation-fetal-clinical-exome-sequencing-comparing-prospective-and-retrospective-cohorts 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/implementation-fetal-clinical-exome-sequencing-comparing-prospective-and-retrospective-cohorts 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/ontogeny-and-vulnerabilities-drug-tolerant-persisters-her2-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/ontogeny-and-vulnerabilities-drug-tolerant-persisters-her2-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/ontogeny-and-vulnerabilities-drug-tolerant-persisters-her2-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/results-single-arm-pilot-study-32p-microparticles-unresectable-locally-advanced-pancreatic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/results-single-arm-pilot-study-32p-microparticles-unresectable-locally-advanced-pancreatic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/results-single-arm-pilot-study-32p-microparticles-unresectable-locally-advanced-pancreatic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/rapid-progression-angioimmunoblastic-t-cell-lymphoma-following-bnt162b2-mrna-vaccine-booster-shot 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/rapid-progression-angioimmunoblastic-t-cell-lymphoma-following-bnt162b2-mrna-vaccine-booster-shot 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/rapid-progression-angioimmunoblastic-t-cell-lymphoma-following-bnt162b2-mrna-vaccine-booster-shot 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/current-landscape-esmoasco-global-curriculum-adoption-and-medical-oncology-recognition-global 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/current-landscape-esmoasco-global-curriculum-adoption-and-medical-oncology-recognition-global 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/current-landscape-esmoasco-global-curriculum-adoption-and-medical-oncology-recognition-global 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/multicenter-external-validation-nomogram-predicting-positive-prostate-specific-membrane 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/multicenter-external-validation-nomogram-predicting-positive-prostate-specific-membrane 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/multicenter-external-validation-nomogram-predicting-positive-prostate-specific-membrane 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/pathologist-annotated-dataset-validating-artificial-intelligence-project-description-and-pilot 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/pathologist-annotated-dataset-validating-artificial-intelligence-project-description-and-pilot 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/pathologist-annotated-dataset-validating-artificial-intelligence-project-description-and-pilot 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/what-if-future-her2-positive-breast-cancer-patients-was-written-mirnas-exploratory-analysis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/what-if-future-her2-positive-breast-cancer-patients-was-written-mirnas-exploratory-analysis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/what-if-future-her2-positive-breast-cancer-patients-was-written-mirnas-exploratory-analysis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/editorial-new-advances-non-small-cell-lung-cancer-management-immune-modulation-and-targeted 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/editorial-new-advances-non-small-cell-lung-cancer-management-immune-modulation-and-targeted 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/editorial-new-advances-non-small-cell-lung-cancer-management-immune-modulation-and-targeted 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/first-human-phase-1-dose-escalation-study-can04-first-class-interleukin-1-receptor-accessory 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/first-human-phase-1-dose-escalation-study-can04-first-class-interleukin-1-receptor-accessory 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/first-human-phase-1-dose-escalation-study-can04-first-class-interleukin-1-receptor-accessory 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/implication-body-mass-index-bmi-biological-and-clinical-effects-endocrine-therapy-plus-abemaciclib 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/implication-body-mass-index-bmi-biological-and-clinical-effects-endocrine-therapy-plus-abemaciclib 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/implication-body-mass-index-bmi-biological-and-clinical-effects-endocrine-therapy-plus-abemaciclib 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/characteristics-and-outcomes-patients-icu-respiratory-syncytial-virus-compared-those-influenza 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/characteristics-and-outcomes-patients-icu-respiratory-syncytial-virus-compared-those-influenza 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/characteristics-and-outcomes-patients-icu-respiratory-syncytial-virus-compared-those-influenza 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/outcome-patients-ultralow-risk-70-gene-signature-mindact-trial 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/outcome-patients-ultralow-risk-70-gene-signature-mindact-trial 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/outcome-patients-ultralow-risk-70-gene-signature-mindact-trial 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/multi-national-survey-experience-and-attitudes-towards-commencing-home-parenteral-nutrition 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/multi-national-survey-experience-and-attitudes-towards-commencing-home-parenteral-nutrition 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/multi-national-survey-experience-and-attitudes-towards-commencing-home-parenteral-nutrition 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/clinical-outcomes-after-proton-beam-therapy-locally-advanced-non-small-cell-lung-cancer-analysis 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/clinical-outcomes-after-proton-beam-therapy-locally-advanced-non-small-cell-lung-cancer-analysis 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/clinical-outcomes-after-proton-beam-therapy-locally-advanced-non-small-cell-lung-cancer-analysis 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/restoring-p53-function-head-and-neck-squamous-cell-carcinoma-improve-treatments 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/restoring-p53-function-head-and-neck-squamous-cell-carcinoma-improve-treatments 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/restoring-p53-function-head-and-neck-squamous-cell-carcinoma-improve-treatments 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/role-intensive-care-unit-after-thoracic-surgery 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/role-intensive-care-unit-after-thoracic-surgery 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/role-intensive-care-unit-after-thoracic-surgery 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/incorporation-tils-daily-breast-cancer-care-how-much-evidence-can-we-bear 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/incorporation-tils-daily-breast-cancer-care-how-much-evidence-can-we-bear 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/incorporation-tils-daily-breast-cancer-care-how-much-evidence-can-we-bear 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/non-invasive-scoring-cellular-atypia-keratinocyte-cancers-3d-lc-oct-images-using-deep-learning 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/non-invasive-scoring-cellular-atypia-keratinocyte-cancers-3d-lc-oct-images-using-deep-learning 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/non-invasive-scoring-cellular-atypia-keratinocyte-cancers-3d-lc-oct-images-using-deep-learning 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/tumor-infiltrating-lymphocyte-stratification-prognostic-staging-early-stage-triple-negative-breast 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/tumor-infiltrating-lymphocyte-stratification-prognostic-staging-early-stage-triple-negative-breast 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/tumor-infiltrating-lymphocyte-stratification-prognostic-staging-early-stage-triple-negative-breast 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/jcog0603-are-we-really-sure-was-negative-trial 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/jcog0603-are-we-really-sure-was-negative-trial 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/jcog0603-are-we-really-sure-was-negative-trial 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/recent-advances-radiosensitivity-determinants-melanoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/recent-advances-radiosensitivity-determinants-melanoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/recent-advances-radiosensitivity-determinants-melanoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/knowledge-practice-and-attitudes-physicians-low-and-middle-income-countries-fertility-and-pregnancy 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/knowledge-practice-and-attitudes-physicians-low-and-middle-income-countries-fertility-and-pregnancy 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/knowledge-practice-and-attitudes-physicians-low-and-middle-income-countries-fertility-and-pregnancy 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/decrease-pancreatic-perfusion-patients-type-2-diabetes-mellitus-detected-perfusion-computed 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/decrease-pancreatic-perfusion-patients-type-2-diabetes-mellitus-detected-perfusion-computed 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/decrease-pancreatic-perfusion-patients-type-2-diabetes-mellitus-detected-perfusion-computed 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/authors-reply-letters-editor-puklin-et-al-and-iyengar-and-ligibel 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/authors-reply-letters-editor-puklin-et-al-and-iyengar-and-ligibel 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/authors-reply-letters-editor-puklin-et-al-and-iyengar-and-ligibel 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/uncovering-role-urinary-microbiota-urological-tumors-systematic-review-literature 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/uncovering-role-urinary-microbiota-urological-tumors-systematic-review-literature 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/uncovering-role-urinary-microbiota-urological-tumors-systematic-review-literature 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/how-we-treat-patients-metastatic-her2-positive-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/how-we-treat-patients-metastatic-her2-positive-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/how-we-treat-patients-metastatic-her2-positive-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/advanced-cutaneous-squamous-cell-carcinoma-head-two-renal-transplanted-patients-treated-cemiplimab 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/advanced-cutaneous-squamous-cell-carcinoma-head-two-renal-transplanted-patients-treated-cemiplimab 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/advanced-cutaneous-squamous-cell-carcinoma-head-two-renal-transplanted-patients-treated-cemiplimab 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/evaluation-cardiotoxicity-her-2-positive-breast-cancer-patients-treated-radiation-therapy-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/evaluation-cardiotoxicity-her-2-positive-breast-cancer-patients-treated-radiation-therapy-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/evaluation-cardiotoxicity-her-2-positive-breast-cancer-patients-treated-radiation-therapy-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/deep-epigastric-lymph-nodes-implication-patients-recurrence-pattern-after-cytoreductive-surgery 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/deep-epigastric-lymph-nodes-implication-patients-recurrence-pattern-after-cytoreductive-surgery 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/deep-epigastric-lymph-nodes-implication-patients-recurrence-pattern-after-cytoreductive-surgery 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/tumor-microenvironment-modifications-recorded-ivim-perfusion-analysis-and-dce-mri-after-neoadjuvant 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/tumor-microenvironment-modifications-recorded-ivim-perfusion-analysis-and-dce-mri-after-neoadjuvant 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/tumor-microenvironment-modifications-recorded-ivim-perfusion-analysis-and-dce-mri-after-neoadjuvant 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/beta-2-adrenergic-receptor-gene-expression-her2-positive-early-stage-breast-cancer-patients-post 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/beta-2-adrenergic-receptor-gene-expression-her2-positive-early-stage-breast-cancer-patients-post 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/beta-2-adrenergic-receptor-gene-expression-her2-positive-early-stage-breast-cancer-patients-post 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/avelumab-neoadjuvant-therapy-patients-urothelial-non-metastatic-muscle-invasive-bladder-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/avelumab-neoadjuvant-therapy-patients-urothelial-non-metastatic-muscle-invasive-bladder-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/avelumab-neoadjuvant-therapy-patients-urothelial-non-metastatic-muscle-invasive-bladder-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/histopathological-growth-patterns-resected-non-colorectal-non-neuroendocrine-liver-metastases 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/histopathological-growth-patterns-resected-non-colorectal-non-neuroendocrine-liver-metastases 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/histopathological-growth-patterns-resected-non-colorectal-non-neuroendocrine-liver-metastases 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/neutrophil-lymphocyte-ratio-prognostic-marker-head-and-neck-cancer-lung-metastasis-retrospective 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/neutrophil-lymphocyte-ratio-prognostic-marker-head-and-neck-cancer-lung-metastasis-retrospective 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/neutrophil-lymphocyte-ratio-prognostic-marker-head-and-neck-cancer-lung-metastasis-retrospective 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/therapeutic-mesenchymal-stemstromal-cells-value-challenges-and-optimization 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/therapeutic-mesenchymal-stemstromal-cells-value-challenges-and-optimization 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/therapeutic-mesenchymal-stemstromal-cells-value-challenges-and-optimization 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/role-pronostique-de-l-irm-prostatique-pre-biopsie-exemple-des-lesions-pirads-5 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/role-pronostique-de-l-irm-prostatique-pre-biopsie-exemple-des-lesions-pirads-5 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/role-pronostique-de-l-irm-prostatique-pre-biopsie-exemple-des-lesions-pirads-5 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/une-nouvelle-therapie-focale-pour-les-patients-atteints-d-un-cancer-localise-de-la-prostate-l 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/une-nouvelle-therapie-focale-pour-les-patients-atteints-d-un-cancer-localise-de-la-prostate-l 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/une-nouvelle-therapie-focale-pour-les-patients-atteints-d-un-cancer-localise-de-la-prostate-l 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/le-role-des-biopsies-peri-lesionnelles-associees-aux-biopsies-ciblees-irmechographie-pour-ameliorer 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/le-role-des-biopsies-peri-lesionnelles-associees-aux-biopsies-ciblees-irmechographie-pour-ameliorer 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/le-role-des-biopsies-peri-lesionnelles-associees-aux-biopsies-ciblees-irmechographie-pour-ameliorer 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/temper-specialist-nurses-heterogeneity-interest-quality-practice-and-mobility-18-eu-countries-study 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/temper-specialist-nurses-heterogeneity-interest-quality-practice-and-mobility-18-eu-countries-study 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/temper-specialist-nurses-heterogeneity-interest-quality-practice-and-mobility-18-eu-countries-study 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/toward-targeted-therapies-oesophageal-cancers-overview 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/toward-targeted-therapies-oesophageal-cancers-overview 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/toward-targeted-therapies-oesophageal-cancers-overview 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/use-pan-tropomyosin-receptor-kinase-immunohistochemistry-screening-tool-detection-neurotrophic 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/use-pan-tropomyosin-receptor-kinase-immunohistochemistry-screening-tool-detection-neurotrophic 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/use-pan-tropomyosin-receptor-kinase-immunohistochemistry-screening-tool-detection-neurotrophic 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/modeling-prognostic-impact-circulating-tumor-cells-enumeration-metastatic-breast-cancer-clinical 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/modeling-prognostic-impact-circulating-tumor-cells-enumeration-metastatic-breast-cancer-clinical 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/modeling-prognostic-impact-circulating-tumor-cells-enumeration-metastatic-breast-cancer-clinical 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/endoscopic-submucosal-dissection-solitary-gastric-plasmacytoma-third-space-oddity 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/endoscopic-submucosal-dissection-solitary-gastric-plasmacytoma-third-space-oddity 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/endoscopic-submucosal-dissection-solitary-gastric-plasmacytoma-third-space-oddity 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/molecular-diagnosis-and-targeted-treatment-advanced-follicular-cell-derived-thyroid-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/molecular-diagnosis-and-targeted-treatment-advanced-follicular-cell-derived-thyroid-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/molecular-diagnosis-and-targeted-treatment-advanced-follicular-cell-derived-thyroid-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/differential-biological-effects-dietary-lipids-and-irradiation-aorta-aortic-valve-and-mitral-valve 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/differential-biological-effects-dietary-lipids-and-irradiation-aorta-aortic-valve-and-mitral-valve 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/differential-biological-effects-dietary-lipids-and-irradiation-aorta-aortic-valve-and-mitral-valve 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/first-ones-now-will-later-be-last-understanding-importance-historical-context-when-reading-esmo 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/first-ones-now-will-later-be-last-understanding-importance-historical-context-when-reading-esmo 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/first-ones-now-will-later-be-last-understanding-importance-historical-context-when-reading-esmo 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/author-correction-fdg-positron-emission-tomography-imaging-and-ctdna-detection-early-dynamic 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/author-correction-fdg-positron-emission-tomography-imaging-and-ctdna-detection-early-dynamic 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/author-correction-fdg-positron-emission-tomography-imaging-and-ctdna-detection-early-dynamic 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/impact-covid-19-pandemic-breast-cancer-management-portugal-cross-sectional-survey-based-study 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/impact-covid-19-pandemic-breast-cancer-management-portugal-cross-sectional-survey-based-study 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/impact-covid-19-pandemic-breast-cancer-management-portugal-cross-sectional-survey-based-study 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/polypoid-colon-mucosa-leukemia-patient 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/polypoid-colon-mucosa-leukemia-patient 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/polypoid-colon-mucosa-leukemia-patient 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/six-year-absolute-invasive-disease-free-survival-benefit-adding-adjuvant-pertuzumab-trastuzumab-and 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/six-year-absolute-invasive-disease-free-survival-benefit-adding-adjuvant-pertuzumab-trastuzumab-and 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/six-year-absolute-invasive-disease-free-survival-benefit-adding-adjuvant-pertuzumab-trastuzumab-and 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/characterization-immunoactive-and-immunotolerant-cd4-t-cells-breast-cancer-measuring-activity 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/characterization-immunoactive-and-immunotolerant-cd4-t-cells-breast-cancer-measuring-activity 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/characterization-immunoactive-and-immunotolerant-cd4-t-cells-breast-cancer-measuring-activity 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/deep-epigastric-lymph-node-harvesting-patients-peritoneal-metastases-colorectal-and-ovarian-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/deep-epigastric-lymph-node-harvesting-patients-peritoneal-metastases-colorectal-and-ovarian-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/deep-epigastric-lymph-node-harvesting-patients-peritoneal-metastases-colorectal-and-ovarian-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/heterotopic-ossification-and-severe-covid-19-infection 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/heterotopic-ossification-and-severe-covid-19-infection 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/heterotopic-ossification-and-severe-covid-19-infection 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/antimicrobial-susceptibility-testing-determined-alfred-60ast-alifaxr-multi-sites-lab-performance-s 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/antimicrobial-susceptibility-testing-determined-alfred-60ast-alifaxr-multi-sites-lab-performance-s 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/antimicrobial-susceptibility-testing-determined-alfred-60ast-alifaxr-multi-sites-lab-performance-s 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/serum-thymidine-kinase-activity-patients-hormone-receptor-positive-and-her2-negative-metastatic 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/serum-thymidine-kinase-activity-patients-hormone-receptor-positive-and-her2-negative-metastatic 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/serum-thymidine-kinase-activity-patients-hormone-receptor-positive-and-her2-negative-metastatic 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/code-practice-needed-samples-donated-trial-participants 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/code-practice-needed-samples-donated-trial-participants 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/code-practice-needed-samples-donated-trial-participants 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/brentuximab-vedotin-and-pembrolizumab-combination-patients-relapsedrefractory-hodgkin-lymphoma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/brentuximab-vedotin-and-pembrolizumab-combination-patients-relapsedrefractory-hodgkin-lymphoma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/brentuximab-vedotin-and-pembrolizumab-combination-patients-relapsedrefractory-hodgkin-lymphoma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/fragility-fractures-postmenopausal-women-development-5-year-prediction-models-using-frisbee-study 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/fragility-fractures-postmenopausal-women-development-5-year-prediction-models-using-frisbee-study 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/fragility-fractures-postmenopausal-women-development-5-year-prediction-models-using-frisbee-study 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/eanm-procedure-guideline-treatment-liver-cancer-and-liver-metastases-intra-arterial-radioactive 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/eanm-procedure-guideline-treatment-liver-cancer-and-liver-metastases-intra-arterial-radioactive 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/eanm-procedure-guideline-treatment-liver-cancer-and-liver-metastases-intra-arterial-radioactive 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/progress-and-pitfalls-use-immunotherapy-patients-triple-negative-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/progress-and-pitfalls-use-immunotherapy-patients-triple-negative-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/progress-and-pitfalls-use-immunotherapy-patients-triple-negative-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/esmo-congress-2021-highlights-eortc-gastrointestinal-tract-cancer-group-s-perspective 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/esmo-congress-2021-highlights-eortc-gastrointestinal-tract-cancer-group-s-perspective 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/esmo-congress-2021-highlights-eortc-gastrointestinal-tract-cancer-group-s-perspective 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/evaluation-comprehensive-geriatric-assessment-cga-tool-predictor-postoperative-complications 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/evaluation-comprehensive-geriatric-assessment-cga-tool-predictor-postoperative-complications 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/evaluation-comprehensive-geriatric-assessment-cga-tool-predictor-postoperative-complications 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/line-field-confocal-optical-coherence-tomography-basosquamous-carcinoma-case-series 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/line-field-confocal-optical-coherence-tomography-basosquamous-carcinoma-case-series 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/line-field-confocal-optical-coherence-tomography-basosquamous-carcinoma-case-series 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/role-perilesional-and-multiparametric-resonance-imaging-targeted-biopsies-reduce-risk-upgrading 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/role-perilesional-and-multiparametric-resonance-imaging-targeted-biopsies-reduce-risk-upgrading 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/role-perilesional-and-multiparametric-resonance-imaging-targeted-biopsies-reduce-risk-upgrading 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/3rd-estro-efomp-core-curriculum-medical-physics-experts-radiotherapy 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/3rd-estro-efomp-core-curriculum-medical-physics-experts-radiotherapy 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/3rd-estro-efomp-core-curriculum-medical-physics-experts-radiotherapy 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/role-psma-radioligands-diagnosis-and-treatment-prostate-carcinoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/role-psma-radioligands-diagnosis-and-treatment-prostate-carcinoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/role-psma-radioligands-diagnosis-and-treatment-prostate-carcinoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/atypical-behavior-metastatic-lung-disease-young-woman-osteosarcoma-case-report 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/atypical-behavior-metastatic-lung-disease-young-woman-osteosarcoma-case-report 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/atypical-behavior-metastatic-lung-disease-young-woman-osteosarcoma-case-report 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/association-between-patient-characteristics-and-efficacy-and-safety-selinexor-diffuse-large-b-cell 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/association-between-patient-characteristics-and-efficacy-and-safety-selinexor-diffuse-large-b-cell 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/association-between-patient-characteristics-and-efficacy-and-safety-selinexor-diffuse-large-b-cell 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/real-world-effectiveness-palbociclib-plus-fulvestrant-advanced-breast-cancer-results-population 2024-03-03T07:00:03+01:00 0.5